 CS. Tick the ECG sign of sinus bradycardia: a) [] PQ interval 0.22 sec b) [] Irregular RR intervals c) [] Atrial and ventricular frequency >70 b/min d) [] QRS complex more than 0.14 mm/sec e) [] Atrial and ventricular frequency < 60 b/min
 2. CS. Thick the excepting ECG sign in sinusal tachycardia: a) [] RR intervals regular b) [] Atrial and ventricular frequency > 100 b / min c) [] PQ interval 0.2 sec d) [] QRS complex duration 0.1 sec e) [] Presence of P waves before each QRST complex
 3. CS. Tick the ECG sign of respiratory arrhythmia: a) [] QRS complex is more than 0.1 sec b) [] Missing P wave before QRS c) [] Present of "F" wave between the QRST complexes d) [] Cyclical shortening intervals R - R in inspiration e) [] Cyclical lengthening intervals R - R to inspiration missing
 4. CS. Mention the clinical sign of paroxysmal supraventricular tachycardia: a) [] High heart rate b) [] Tachycardia onset is sudden c) [] Tachycardia onset is gradual d) [] Vagal maneuvers stops tachycardia attack e) [] Tachycardia attack stops sudden
 5. CS. Tick the ECG sign in reciprocal atrioventricular tachycardia with acceding ways: a) [] PQ interval 0.2 mm sec b) [] Negative P waves in DII, DIII, aVF and positive in aVR following QRS c) [] Irregular RR interval d) [] QRS duration > 0.14 sec. e) [] Usually aberrant QRS complex
 6. CS. Tick the ECG sign of paroxysmal ventricular tachycardia: a) [] Abnormal QRS complex, with secondary changes in ST, T b) [] Negative P wave before QRS c) [] Presence of delta wave d) [] PQ interval <0.12 sec e) [] Negative P waves after QRS complex
 7. CS. Tick the ECG sign for atrial extrasystoles: a) [] "f" wave between RR intervals b) [] PQ interval< 0.12 sec c) [] Premature P wave before QRST complex d) [] Full compensatory pause e) [] Absence of P wave before QRST complex

 8. CS. Tick the excepting ECG sign for ventricular extrasystoles: a) [] Normal PQ interval b) [] ST segment and T wave are opposite to the main deflexion QRS complex
c) [] Full compensatory paused) [] Negative P wave after QRS complex
e) [] QRS duration > 0.12 sec
9. CS. Thick the excepting ECG signs for atrial flutter:a) [] Atrial frequency contractions 300 b / min
b) [] Propagation of atrial impulses to the ventricles in relation 2:1 c) [] QRS complex usually normal
d) [] "F" wave between where RR-looking like a saw tooth e) [] Incomplete compensatory pause
10. CS. Choose the main method in treatment of instable hemodynamic ventricular tachycardia: a[] Electric shock application 75-100 J
b) [] Intravenous Sol. Novocainamidc) [] Intravenous Sol Digoxin
d) [] Electric shock application 50 Je) [] Intramuscular Sol. Lidocaine
11. CM. Mention what includes the ECG classification of tachyarrhythmia
a) [] Wide QRS complex tachyarrhythmiab) [] Narrow QRS complex tachyarrhythmia
c) [] Normal PQ interval tachyarrhythmiad) [] Lengthened PQ interval
e) [] With ST segment elevation tachyarrhythmia
12. CM. Thick the ECG signs of atrial fibrillation: a) [] Irregular RR intervals
b) [] "F" wave between RR-looking saw tooth
c) [] Absence of P-waved) [] "f" wave between RR intervals
e) [] PQ intervalle duration 0.14 sec
13. CM. Tick the most common causes of atrial fibrillation:a) [] Mitral stenosis
b) [] Thyrotoxicosisc) [] Alcoholic cardiomyopathy
d) [] Mixedema
e) [] Atrial septal defect type "ostium secundum"
14. CM. Mention what includes atrial fibrillation classification:a) [] Acute atrial fibrillation
b) [] Chronic atrial fibrillationc) [] Paroxysmal atrial fibrillation
d) [] Persistent atrial fibrillatione) [] Relapsing atrial fibrillation

 15. CM. Choose correct statements of "vagal" paroxysmal atrial fibrillation: a) [] is more frequently in women b) [] Stand by is triggered c) [] Is more common in men d) [] It appears during emotional stress e) [] It begin postprandial or during sleep
 16. CM. Choose the correct statements about "adrenergic" paroxysmal atrial fibrillation: a) [] Occurs during exercise b) [] Is caused by stressful situations c) [] Mainly in the morning d) [] Meets more frequently in women's e) [] Stand by fires
 17. CM. Tick the drugs that inhibit the impulse through the atrioventricular node: a) [] Digoxin b) [] Propronalol c) [] Amiodarone d) [] Verapamil e) [] Nifedipine
18. CM. Choose the medicines used to restore sinus rhythm in atrial fibrillation: a) [] Digoxin b) [] Novocainamid c) [] Amiodarone d) [] Propafenone e) [] Sotalol
 19. CM. Mention the atrial fibrillation thromboembolic risk factors: a) [] Age > 60 years b) [] Arterial hypertension c) [] Diabetes mellitus d) [] History of stroke e) [] Overweight
 20. CM. Mention the characteristic of ventricular flutter: a) [] syncope b) [] "F" wave between RR-looking saw tooth c) [] absence of peripheral pulse d) [] presence of sinusoidal regular waves e) [] heart rates 250 -300 per min
21. CM. Mention the characteristics of ventricular fibrillation: a) [] Delta waves on ECG b) [] Lack of QRS complexes c) [] Syncope d) [] Presence of distorted, irregular, chaotic waves on ECG e) [] Presence of "f" waves between QRS

 22. CM. Indicate the effective resuscitation measures in ventricular fibrillation and flutter: a) [] Blow in the chest in the first few seconds b) [] Initial electrical cardioversion with 200 J c) [] Electrical cardioversion with 320 - 400 J in unloading effect d) [] Cardiac massage correctly done in the first minutes e) [] Sol. Lidocaine intravenous
 23. CM. Indicate the characteristics of sinus tachycardia: a) [] Gradually heart rate increase b) [] Normal physiological response to physical exertion c) [] QRS complex is normal d) [] PQ interval is more 0.20 sec. e) [] The pace is accelerating in inspiration and reduced on expiration
 24. CM. Indicate the causes of sinus tachycardia: a) [] Vagus nerve hyper tonus b) [] Alcohol abuse c) [] Fever d) [] Thyrotoxicosis e) [] Cord pulmonale
25. CM. Indicate the causes of junctional nonparoxistic atrioventricular tachycardia: a) [] Cardiac glycosides poisoning b) [] Inferior myocardial infarction c) [] Hypokalemia d) [] Heart surgery intervention e) [] Hypocalcaemia
 26. CM. Indicate the causes of reciprocal junctional atrioventricular tachycardia: a) [] Atrial and ventricles depolarization is concomitant b) [] Impulse circulating into the atrioventricular node c) [] Anterograde ventricular activation of His - Purkinje system d) [] Retrograde activation of the atria e) [] Atria depolarization precedes ventricular depolarization
27. CM. Indicate the treatment of atrioventricular reciprocal tachycardia: a) [] Application of vagal maneuvers b) [] Face immersion in cold water with breath retention for 10-30 sec c) [] Sol. Adenosine triphosphate intravenous d) [] External electric shock with 200 J e) [] Trans esophageal heart electric stimulation
 28. CM. Indicate the characteristics of paroxysmal ventricular tachycardia: a) [] Regular ventricular rhythm b) [] Effectiveness of vagal maneuvers in treatment c) [] Abnormal QRS complex with ST,T secondary changes d) [] PQ interval prolongation e) [] Presence of "f" wave on ECG

 29. CM. Choose the antiarrhythmic drugs recommended stopping ventricular tachycardia: a) [] Digoxin b) [] Lidocaine c) [] Amiodarone d) [] Disopyramide e) [] Novocainamid
 30. CM. Indicate the ECG characteristics of atrial extrasystoles: a) [] Normal QRS complex b) [] Lack of P wave c) [] Negative P wave after QRS complex d) [] Incomplete compensatory pause e) [] Premature P wave preceding QRS complex
 31. CM. Choose the signs of polymorphic premature heart beats: a) [] Varying coupling intervals b) [] Extrasystoles in the same lead have different forms c) [] Extrasystoles in the same lead have equal forms d) [] Coupling intervals are equal e) [] Different outbreaks extrasystoles
 32. CM. Indicate the ECG signs of ventricular extrasystoles: a) [] QRS complex pathological b) [] Full compensatory pause c) [] P-Q interval less than 0.12 sec d) [] Negative P wave, succeeded QRS e) [] Lack of P wave
 33. CM. Indicate the ECG signs of superior atrioventricular extrasystoles: a) [] PQ interval over 0.20 sec b) [] Normal QRS complex c) [] P wave negative in DII, DIII before the QRS complex d) [] P wave negative in DII, DIII QRS after QRS e) [] Incomplete compensatory pause
34. CM. Tick the ECG manifestations of middle atrioventricular extrasystoles: a) [] QRS complex usually normal b) [] P wave negative in DII, DIII subsequent to QRS c) [] P wave is embedded in QRS complex d) [] Full compensatory pause e) [] P wave negative in DII, DIII precede QRS complex
35. CM. Choose the ECG signs of atrioventricular extrasystoles: a) [] Lack of P wave b) [] Normal QRS complex c) [] Incomplete compensatory pause d) [] Negative P wave after QRS complex e) [] Wide QRS complex

 36. CM. Mention what includes Lawn-Wolf classification of extrasystoles: a) [] Class I - solitary monomorphic extrasystoles -> 30 ex / h b) [] Class II - solitary extrasystoles polymorph c) [] Class III - polymorphic ventricular extrasystoles d) [] Class IV - recurrent ventricular extrasystoles (duble, triples, sage) e) [] Class V - early ventricular type " R on T"
 37. CM. Tick the I class of antiarrhythmic drugs: a) [] Lidocaine b) [] Mexilitin c) [] Quinidine d) [] Novocainamid e) [] Amiodarone
 38. CM. Tick the II class of antiarrhythmic drugs: a) [] Amiodarone b) [] Lidocaine c) [] Metoprolol d) [] Nebivolol e) [] Carvedilol
39. CM. Tick the III class of antiarrhythmic drugs: a) [] Lidocaine b) [] Sotalol c) [] Quinidine d) [] Novocainamid e) [] Amiodarone
40. CS. Indicate what conductibility disorder cannot be diagnosed by ECG: a) [] Atrioventricular block I degree b) [] Complete right bundle branch block of His c) [] Sinoatrial block of I degree d) [] Atrioventricular block III degree e) [] Sinoatrial block II degree
41. CS. Choose the ECG sign of sinoatrial block II degree: a) [] Sinusal pauses; no P wave b) [] Periodical lack QRS complexes c) [] Full compensatory pause after PQRST complex d) [] Frequent atrial and ventricular contractions e) [] PQ interval prolongation
 42. CS. Indicate the conductivity disorder characterized by Wenckebach periods on ECG: a) [] II degree atrioventricular block, type II (Mobitz II) b) [] II degree sinoatrial block, type I (Mobitz I) c) [] Third degree atrioventricular block d) [] Right bundle branch block of His e) [] Left bundle branch block of His

 43. CS. Indicate the main clinical feature of advanced sinoatrial and atrioventricular blocks II degree type II (Mobitz II): a) [] Palpitations b) [] Dyspnea on exertion c) [] Fatigabilité d) [] Syncope e) [] Retrosternal pain
 44. CS. Point the ECG signs of atrioventricular block I degree: a) [] Prolonged QRS interval b) [] Negative P waves before QRST complex c) [] PQ or PR intervals more than 0.2 sec d) [] PQ intervals different e) [] Where Delta
 45. CS. Mention the ECG signs of atrioventricular block II degree: a) [] Intermittent lack of PQRST complex b) [] Lack of P wave c) [] Regular lack QRS complexes d) [] Presence of "F" waves e) [] Presence of "f" waves
 46. CS. Choose the definition of III degree atrioventricular block: a) [] None of atrial impulses propagate to the ventricles b) [] Gradual slowing of impulses propagation to the ventricles c) [] Organic lesion of His-Purkinje system d) [] Pausing of the electrical activity of sinus node e) [] Impulses are conducted retrograde from the ventricles to the atria
 47. CS. Choose the ECG signs of III degree atrioventricular block: a) [] Atrial - ventricular contractions ratio is 3:1 b) [] Independent atrial and ventricular contractions c) [] Sinus pause without P wave d) [] Irregular lack of PQRST complexes e) [] Regular QRST complexes lack
48. CS. Mention the ECG signs of complete right bundle branch block Hiss: a) [] Presence of large R wave, crocheted in III, AVF, V1, V2 b) [] PQ interval prolongation c) [] PQ interval shortening d) [] R wide, crocheted in I, AVL, V5, V6 e) [] S is larger in III, AVF, V1, V2
49. CS. Mention the ECG signs of complete left bundle branch block Hiss: a) [] presence of wide R wave, jagged in III, AVF, V1, V2 b) [] PQ interval prolongation c) [] PQ interval shortening d) [] Wide, jagged R wave in I, AVL, V5, V6 e) [] S range in I, AVL, V5, V6

50. CS. Mention the indication for cardioverter-defibrillator implantation: a) [] Ventricular fibrillation recurrences at varying intervals of time b) [] Complete atrioventricular block c) [] Atrial fibrillation d) [] Atrial flutter e) [] Complete sinoatrial block
51. CM. Indicate the causes of asistolia: a) [] Atrioventricular block III degree b) [] Atrioventricular block I degree c) [] Ectopic rhythm from the middle of atrioventricular junction d) [] Complete sinoatrial block e) [] Permanent atrial fibrillation
52. CM. Indicate the causes of abnormal automatism: a) [] Myocardial fibers extension b) [] Electrolyte disbalance c) [] Catecholamine influence d) [] Myocardial infarction e) [] Anemia
53. CM. Indicate the electrophysiological mechanisms of arrhythmias: a) [] Decreasing of normal automatism b) [] Increasing of normal automatism c) [] Presence of pathological automatism d) [] Early post depolarization e) [] Late post depolarization
54. CM. Choose the ECG characteristics of II degree sinoatrial block type II (Mobitz II): a) [] Regular PP intervals b) [] Incomplete compensatory pause after PQRST complex c) [] Sinusal pause, no P wave d) [] Pause duration corresponding to 2, 3 or more PP normal intervals e) [] Pause is preceded by progressive decrease in PP intervals
55. CM. Choose the signs of classic Morgan - Adams - Stocks syndrome: a) [] Hypertension b) [] Sudden onset c) [] Syncope with pronounced pale skin d) [] Reactive hyperemia after attack e) [] Intermittent character
56. CM. Indicate the correct statements of atrioventricular block I degree: a) [] Keeping all atrial impulses to the ventricles b) [] PQ or PR interval over 0.2 sec c) [] Is common in the elderly d) [] PQ or PR interval less than 0.12 sec. e) [] Gradual lengthening of the PQ interval

 57. CM. Indicate the ECG signs of II degree atrioventricular block type I (Mobitz I): a) [] Progressive lengthening of PQ or PR interval b) [] Omission of ventricular contraction c) [] The presence of Wenckebach periods Samoilov d) [] Irregular RR intervals e) [] Regular RR intervals
58. CM. Indicate the ECG characteristic of atrioventricular block II degree, type II (Mobitz II): a) [] Wenckebach periods b) [] Irregular RR intervals c) [] Not all atrial impulses are propagated to the ventricles d) [] The ECG recorded absence of 1, 2, 3QRS complex e) [] Organic involvement of conductibility heart system
 59. CS. Indicate what with is combined atrial fibrillation in Frederic syndrome: a) [] Atrioventricular block II degree, type II b) [] Complete sinoatrial block c) [] Frequent atrial extrasystoles d) [] Frequent ventricular extrasystoles e) [] Complete atrioventricular block
60. CM. Mention the characteristics of III degree atrioventricular block located in the AV node: a) [] It is often congenital b) [] In most patients AV junctional rhythm is registered with the heart rate40-60 b / min c) [] During exercise and stress the heart rates is accelerating up to 100 b / min d) [] Heart rates does not exceed 40 b / min e) [] It is almost always acquired
61. CM. Indicate the characteristics of III degree atrioventricular block in the Hiss - Purkinje system: a) [] It is often congenital b) [] Syncope states c) [] Heart rates are accelerating up to 100 b / min during exercise and stress d) [] The rate does not exceed 40 b / min e) [] It is almost always acquired
62. CM. Choose the rhythm disorders manifested with syncopal states: a) [] Ventriculaire fibrillation b) [] Atrial fibrillation c) [] Ventricular flutter d) [] Ventricular tachycardia e) [] Complete atrioventricular block
 63. CM. Mention the ECG signs of complete left bundle branch block Hiss: a) [] QRS duration exceeding 0.12 sec. b) [] S-ventricular complex in III, AVF, V1, V2 c) [] S-ventricular complex in I, AVL, V5, V6 d) [] Ventricular complex type R in I, AVL, V5, V6

e) [] QRS duration from 0.10 to 0.12 sec.
64. CM. Indicate the ECG signs of incomplete right bundle branch block Hiss: a) [] Widening of QRS complexes over 0.12 sec b) [] Ventricular complex in leads RSR type III, AVF, V1, V2 c) [] Absence and presence of Q waves in leads V5 wide S waves, V6 d) [] Ventricular rhythm e) [] QRS duration from 0.10 to 0.12 sec
65. CM. Indicate the correct statements Wolff-Parkinson-White syndrome: a) [] The presence of a pathway directly linking accessories atrium of the ventricles b) [] Atrial impulse propagated simultaneously towards node Hiss and f. Kent c) [] Early ventricles depolarization d) [] Presence of delta wave on ECG e) [] PQ interval within 0.12 to 0.20 sec
66. CM. Indicate the characteristics of incomplete left bundle branch block Hiss: a) [] "R" type complex in I, AVL, V5, V6 b) [] Electric axis suddenly diverted to the left c) [] S complex type III, AVF, V1, V2 d) [] QRS duration from 0.1 to 0.12 sec e) [] Junctional rhythm
67. CM. Choose the ECG manifestation of Wolff-Parkinson-White syndrome: a) [] Presence of delta wave b) [] RR intervals equal c) [] Normal P wave and PQ interval less that 0.12 sec d) [] PQ interval over 0.18 seconds e) [] Progressive lengthening of the interval PQ
68. CM. Indicate the indications for implantation of permanent cardiostimulation: a) [] Complete atrioventricular block associated with symptomatic bradycardia b) [] Frederick syndrome c) [] Recurrent syncope associated with systolic intervals over 3 sec. d) [] Persistent post infarction atrioventricular block II degree e) [] Ventricular fibrillation
69. CM. Choose the indications for trans esophageal electro cardio stimulation: a) [] Atrial flutter b) [] Paroxysmal AV reciprocal tachycardia c) [] Ventriculaire fibrillation d) [] Ventriculaire Flutter e) [] Bifascicular block
 70. CM. Specify conduction disorders that can be diagnosed by ECG: a) [] I-st degree atrioventricular block b) [] Complete right bundle branch block c) [] I-st degree sinoatrial block d) [] III-rd degree atrioventricular block

e) [] II-nd degree sinoatrial block
71. CM. Indicate the ECG signs of II degree sinoatrial block: a) [] Sinusal arest periods without P waves b) [] Periodic lack of PQRS complexes c) [] Complete compensatory pause after PQRST complex d) [] Frequent atrial and ventricular contractions e) [] PQ intervale prolongation
 72. CM. Indicate the conduction disorders characterized by Wenckebach periods on ECG: a) [] II-nd degree sinoatrial block, tiype I (Mobitz I) b) [] II-nd degree sinoatrial block, tip II (Mobitz II) c) [] III-rd degree atrioventricular block d) [] Complete right bundle branch block e) [] Left bundle branch block
 73. CM. Indicate the clinical features of II-nd degree sinoatrial and atrioventricular type II (Mobitz II) block: a) [] Palpitations b) [] Exertional mixed dyspnea at moderate stress c) [] Presyncope d) [] Syncope e) [] Constrictive chest pain
74. CM. Point out ECG signs of the I-st degree AV block: a) [] Prolonged QRS interval b) [] Negative P waves before QRST complexes c) [] PQ or PR intervals more than 0,2 sec. d) [] Equal PQ intervals e) [] Delta waves
 75. CM. Mention the ECG sign of II-nd degree AV block: a) [] Recurrent lack of QRST complex b) [] Absence of P wave c) [] Solitary P wave without ORSTcomplex d) [] "f" waves e) [] "F" waves
 76. CM. Indicate the ECG signs of the III-rd degree atrioventricular block: a) [] None of atrial impulses pass to ventricles b) [] Independent atrial and ventricular contractions c) [] Organic lesion of sinoatrial node d) [] Temporary stop of the electrical activity of the sinus node e) [] Impulses are conducted retrograde from ventricles to the atria
77. CM. Mention the ECG sign of III-rd degree AV block: a) [] independent atrial and ventricular depolarization b) [] Morgan - Adams - Stocs attack c) [] Syncope

d) [] Periodical lack of PQRST complexese) [] Periodical lack of QRST complexes
78. CS. Indicate what disease is infective endocarditis: a) [] Degenerative b) [] Destructive c) [] Infectious d) [] Congenital e) [] Acquired
79. CS. Mention what structure is less involved in infective endocarditis: a) [] Mitral valve b) [] Aortic valve c) [] Tricuspid valve d) [] Pulmonary artery valve e) [] Eustache valve
80. CS. Indicate the most common infection in intravenous drug users and prosthetic valves infectious endocarditis: a) [] Streptococcus virdans b) [] Streptococcus β hémolytique c) [] Staphylococcus aureus d) [] Staphylococcus epidermal e) [] Enterococcusus fecalis
81. CS. Mention who the first described infectious endocarditis: a) [] Libman E. b) [] Osler W. c) [] Schottmuller H. d) [] Thayer's W. e) [] Jaccoud S.
 82. CS. Choose the avoided medication in infectious endocarditis treatment: a) [] Antibiotics b) [] Antifungal c) [] Glycosides d) [] Anticoagulants e) [] β-blockers
83. CS. Indicate the method of treatment with Amoxicillin in infectious endocarditis prevention: a) [] 0,5 g - 2 hours before dental procedure b) [] 0,5g - after the dental procedure c) [] 2 g - 30 min before procedure d) [] 1 g -2 hours before dental procedure e) [] 0,5 g in 4 divided doses
84. CS. Choose the recommended drug in methicillin-resistant streptococcal endocarditis: a) [] Penicillin G b) [] Ceftriaxone

c) [] Vancomycin d) [] Gentamicin is. e) [] Amoxicillin
85. CS. Indicate the most common and serious complication of infectious endocarditis: a) [] Embolic events b) [] Heart failure "Osler" type c) [] Glomerulonephritis d) [] Encephalitis e) [] Toxic hepatitis
86. CS. Indicate the most informative laboratory test in infective endocarditis: a) [] Troponin b) [] Urea c) [] C-reactive protein d) [] Blood culture e) [] Urine culture
87. CM. Mention the localization of vegetation's in infective endocarditis: a) [] Native valves b) [] Eustache valve c) [] Ileocecal valve d) [] Prosthetic valves e) [] Ventricular septal defect
 88. CM. Indicate the major diagnostic criteria of infective endocarditis: a) [] Fever ≥ 38 C b) [] Fever ≤ 38 C c) [] Positive blood culture in three peripheral veins d) [] Positive blood cultures from a single sample e) [] The presence of vegetation on echocardiography
89. CM. Choose the main clinical manifestations of infectious endocarditis: a) [] Diarrhea b) [] Vomiting c) [] Chills d) [] Sweating e) [] Fever
 90. CM. Indicate the most common complications of right heart endocarditis: a) [] Septic pneumonia b) [] Destructive multifocal pneumonia c) [] Cerebral embolism d) [] Coronary embolism e) [] Pulmonar abscess
91. CM. Thick the embolic complications of left heart endocarditis: a) [] Renal emboli b) [] Cerebral embolism

 c) [] Splenic embolism d) [] Cardiac emboli e) [] Thromboembolism
 92. CM. Indicate the absolute indications for in infectious endocarditis prevention: a) [] Mitral valve prolapse b) [] Ischemic Heart Diseases c) [] Hypertrophic cardiomyopathy d) [] Prosthetic valves e) [] Infective endocarditis in antecedence
 93. CM. Indicate the criteria of activity in infective endocarditis: a) [] Two months from onset b) [] Persistent fever regardless of disease duration c) [] Endocardial inflammation by morphological examination d) [] Positive blood cultures e) [] Pathogenic detection in nasopharynx smears
 94. CM. Indicate the correct statements of early prosthetic endocarditis: a) [] Staphylococcus and streptococcus are predominant infectious agents' b) [] Embolic complications are the cause high rate mortality c) [] Develops in the first 12 months after valve replacement d) [] Develops in the first 24 months after valve replacement e) [] Also is called nosocomial endocarditis
95. CM. Mention what included the treatment of heart failure in endocarditis: a) [] Surgical correction of the valvulopathy b) [] Glycosides c) [] Diuretics d) [] Glucocorticosteroids e) [] Enzyme Converting Inhibitors
96. CM. Indicate the indications for surgical treatment in infectious endocarditis: a) [] Fungal endocarditis b) [] Streptococcal endocarditis c) [] Myocardial abscess d) [] Glomerulonephritis e) [] Resistant to antibacterial therapy
 97. CM. Indicate the correct statements about infectious endocarditis: a) [] Infectious disease b) [] Vegetation lesions of native valves c) [] Dehiscence of prosthesis d) [] Positive blood cultures e) [] Positive smear from nasopharynx
98. CM. Indicate what involves infectious endocarditis:a) [] Native valvesb) [] Mechanical prosthetic valves

c) [] Biological prosthetic valves d) [] Intact valves e) [] Ileocecale valves
99. CS. Indicate the predominant infectious agent of prosthetic valves infectious endocarditis: a) [] Streptococcus virdans b) [] Streptococcus bovis c) [] Enterococcus faecalis d) [] Staphylococcus epidermidis e) [] Staphylococcus aureus
100. CS. Choose the predominant infectious agent of intravenous drug user's infectious endocarditis: a) [] Staphylococcus epidermidis b) [] Staphylococcus aureus c) [] Streptococcus virdans d) [] Streptococcus bovis e) [] Enterococcus faecalis
 101. CS. Indicate the predominant infectious agent in infectious endocarditis in insufficient dental hygiene: a) [] Streptococcus virdans b) [] Streptococcus bovis c) [] Enterococcus faecalis d) [] Staphylococcus epidermidis e) [] Staphylococcus aureus
102. CM. Indicate who have dealt with research in the field of infectious endocarditis: a) [] Libman E. b) [] Osler W. c) [] Schottmuller H. d) [] Nicolaev L. e) [] Socoteanu V.
103. CM. Indicate the drugs in treatment of infectious endocarditis: a) [] Antibiotics b) [] Antifungal c) [] Cardiac glycosides d) [] Anticoagulants e) [] Beta blockers
104. CS. Choose the dose and administration of Daptomycin in patients with infectious endocarditis caused by Staphylococcus aureus: a) [] 0,5 g per day intravenous infusion b) [] 1g per day intravenous bolus c) [] 3 g per day orally d) [] 1 g per day orally e) [] 0,5 g per day divided in 4 doses intramuscularly

 105. CS. Indicate the dose of Vancomycin in patients with infectious endocarditis caused by Staphylococcus methicillin resistant: a) [] 0,5 g per day intravenous infusion b) [] 1 g per day intravenous infusion c) [] 2 g per day intravenous infusion in 2 doses d) [] 0,5 g per day intravenous bolus e) [] 1 g per day intravenous bolus
106. CM. Choose the drugs for treatment of methicillin resistant Staphylococcal infectious endocarditis: a) [] Penicillin G b) [] Daptomycin c) [] Vancomycin d) [] Gentamicin e) [] Amoxicillin
 107. CM. Indicate the complications of infectious endocarditis: a) [] Glomerulonephritis b) [] Embolism c) [] Heart failure d) [] Torticollis e) [] Toxic hepatitis
108. CM. Indicate the most informative investigations in diagnosis of infectious endocarditis: a) [] Echocardiography b) [] Electrocardiography c) [] C-reactive protein d) [] Blood culture e) [] Uroculture
109. CS. Choose the incorrect location of microbial infectious endocarditis in graft: a) [] Native valves b) [] Eustachian valve c) [] Ileocecal valve d) [] Valvular prostheses e) [] Intact valves
 110. CM. Choose the major criteria for the diagnosis of infective endocarditis are: a) [] Fever ≥ 38°C b) [] Myocardial abscess on echocardiography c) [] Positive blood culture in three peripheral veins d) [] Dehiscence of prosthesis at echocardiography e) [] The presence of vegetation on echocardiography
 111. CS. Indicate the location of emboli in right heart infectious endocarditis: a) [] Pulmonary b) [] Coronary c) [] Cerebral d) [] Mesenteries

e) [] Splenic
112. CS. Choose the incorrect complications for left heart infectious endocarditis: a) [] Renal embolisms b) [] Cerebral embolisms c) [] Splenic embolisms d) [] Coronary embolisms e) [] Pulmonary embolisms
 113. CM. Choose the patients for infectious endocarditis prophylaxis: a) [] Mitral valve prolapse b) [] Ischemic heart disease c) [] Hypertrophic cardiomyopathies d) [] Valvular prostheses e) [] Infectious endocarditis in the past
 114. CM. Select the criteria of activity in infectious endocarditis: a) [] First two months from onset b) [] Persistent fiver c) [] Endocardial inflammation by morphological examination d) [] Positive blood cultures e) [] Detection of the pathogen through the smear from nasopharynx
 115. CM. Indicate the correct statements for early prosthetic infectious endocarditis: a) [] Staphylococcus and streptococcus etiology b) [] High risk of embolic complications and death c) [] Develops in the first 6 months after prosthesis d) [] It is communitarian infectious endocarditis e) [] It is nosocomial endocarditis
116. CM. Select the methods of treatment of heart failure in infectious endocarditis: a) [] Surgical correction of valvulopathy b) [] Administration of cardiac glycosides c) [] Administration of diuretics d) [] Administration of steroids e) [] Administration of vasodilators
117. CM. Select the indication for surgical treatment in infectious endocarditis: a) [] Fungal endocarditis b) [] Streptococcal endocarditis c) [] Infectious endocarditis complicated with myocardial abscess d) [] Infectious endocarditis complicated with glomerulonephritis e) [] Resistance to antibacterial treatment
 118. CM. Select the minor criteria for diagnosis of infectious endocarditis: a) [] Fever ≥ 38°C b) [] Positive blood culture in one sample c) [] Dehiscence of prosthesis at echocardiography d) [] Suspection of vegetation on echocardiography

e) [] Predisposing cardiac factors
 119. CM. Select the minor DUKE criteria for diagnosis in infectious endocarditis: a) [] Fever ≥ 38°C b) [] Janeway lesions c) [] Positive blood culture in three samples d) [] Osler nodules e) [] Vegetation on echocardiography
 120. CM. Select the minor DUKE criteria for diagnosis infectious endocarditis: a) [] Fever ≥ 38°C b) [] Positive rheumatoid factor c) [] Positive blood culture in three samples d) [] Roth spots e) [] Vegetation on echocardiography
 121. CM. Indicate where located microbial graft in infectious endocarditis: a) [] Native valves b) [] Valvular cordages c) [] Carotid arteries d) [] Ascending aorta e) [] Femoral arteries
 122. CS. Choose the correct statement about late prosthetic infectious endocarditis: a) [] Predominance of staphylococcus etiology b) [] Embolic complications are a high percentage and cause death c) [] Develops in the first 6 months after prosthesis d) [] It is communitarian infectious endocarditis e) [] It is nosocomial infectious endocarditis
123. CM. Select the correct statements for the late prosthetic infectious endocarditis: a) [] Predominance of staphylococci etiology b) [] Embolic complications are a high percentage and cause death c) [] Develops in the first year after surgery d) [] It is communitarian infectious endocarditis e) [] It is nosocomial endocarditis
124. CM. Select the new forms of infectious endocarditis: a) [] Infectious endocarditis in cardiac devices b) [] Infectious endocarditis in the adolescence c) [] Infectious endocarditis in the elderly d) [] Infectious endocarditis of the intravenous drug users e) [] Infectious endocarditis of addicts
 125. CS. Select the incorrect new form of infectious endocarditis: a) [] Intracardiac devices of infectious endocarditis b) [] Infectious endocarditis in the adolescence c) [] Infectious endocarditis in the elderly d) [] Infectious endocarditis of the intravenous drug users

e) [] Infectious endocarditis in patients on hemodialysis
126. CM. Select the predisposing factors for developing of infectious endocarditis: a) [] Congenital heart diseases b) [] Degenerative heart diseases c) [] Hypertrophic heart diseases d) [] Hypertension e) [] Myocardial infarction
127. CM. Select the cardiac predisposing factors for developing of infectious endocarditis: a) [] Bicuspid aortic valve b) [] Mitral stenosis c) [] Ventricular septal defect d) [] Hypertension e) [] Mitral valve prolapse
 128. CS. Select the most common predisposing factor for the development of infectious endocarditis in Republic of Moldova: a) [] Intact valves b) [] Rheumatic valvulopathy c) [] Myocarditis d) [] Hypertension e) [] Hypertrophic heart diseases
129. CS. Indicate the predisposing factor for the development of infectious endocarditis of righ heart: a) [] Dental extractions b) [] Viral hepatitis c) [] Hypertrophic heart diseases d) [] Intravenous drug use e) [] Rheumatic heart disease
130. CM. Select the morbid circumstances (the gateway of infection) in infectious endocarditis a) [] Pneumonia b) [] Dental extractions c) [] Hemodialysis d) [] Poor dental hygiene e) [] Elderly
131. CS. Indicate the most frequent gateway of infectious endocarditis in right heart: a) [] Respiratory infections b) [] Dental extractions c) [] Intravenous drug use d) [] Poor dental hygiene e) [] Elderly
132. CM. Choose the most common comorbidities in infectious endocarditis in Republic of Moldova:

a) [] Liver cirrhosis

b) [] Hepatitis c) [] Diabetes d) [] AIDS e) [] Lues
133. CS. Select the duration of antimicrobial therapy in patients with streptococcal infectious endocarditis: a) [] 1 week b) [] 2 weeks c) [] 3 weeks d) [] 4 weeks e) [] 6 weeks
134. CS. Choose the duration of antimicrobial therapy in prosthetic infectious endocarditis staphylococcal etiology? a) [] 1 week b) [] 4 weeks c) [] 2 weeks d) [] 8 weeks e) [] 10 weeks
 135. CM. Select the criteria of recovery in infectious endocarditis: a) [] Eradication of infection b) [] Normal body temperature c) [] Normal ESR and negative blood cultures within 1 year after treatment d) [] Normal ESR and negative blood cultures within 1 month after treatment e) [] Normal ESR and negative blood cultures within 6 months after treatment
136. CS. Marks the most used laboratory investigation for diagnosis of rheumatic heart diseases: a) [] Electrocardiography b) [] Echocardiography c) [] Phonocardiography d) [] Cardiac CT e) [] MRI of the heart
137. CS. Choose the no characteristic complication of mitral regurgitation: a) [] Atrial fibrillation b) [] Endocarditis c) [] Systemic embolism d) [] Stomach bleeding e) [] Cardiac asthma
138. CS. Select the drugs dont recomanded in mitral regurgitation: a) [] ACE inhibitors b) [] Beta blockers c) [] Diuretics d) [] Cardiac glycosides e) [] Alfa mimetic drugs

 139. CS. Marks the most common rhythm disorder in mitral stenosis: a) [] Sinus bradycardia b) [] Ventricular extrasystoles c) [] Atrial fibrillation d) [] Ventricular fibrillation e) [] Atrioventricular blocks
 140. CS. Tick the cause of angina attacks in mitral stenosis: a) [] Increased blood flow to the heart b) [] Sudden increase in blood in the capillaries c) [] Congestions in small circuit d) [] Left coronary artery compression by increased left atrium e) [] Right coronary artery compression by increased right atrium
141. CS. Indicate the normal surface of aortic orifice: a) [] 2,5 - 3,0 cm ² b) [] 2,0 - 2,5 cm ² c) [] 3,5 - 4,0 cm ² d) [] 1,5 - 2,0 cm ² e) [] 3,0 - 4,0 cm ²
142. CS. Choose wich valvulopathy cause severe left ventricular concentric hypertrophy: a) [] Mitral stenosis b) [] Aortic stenosis c) [] Mitral valve regurgitation d) [] Aortic valve regurgitation e) [] Pulmonary artery regurgitation
143. CS. Mention wich valvulopathy can reach values the diastolic blood pressure to 40-10 mmHg. a) [] Aortic stenosis. b) [] Mitral stenosis c) [] Pulmonary artery stenosis d) [] Mitral valve regurgitation e) [] Aortic valve regurgitation
144. CS. Indicate the normal value of heart ejection fraction: a) [] ≥50 % b) [] 80-100% c) [] 90-95% d) [] 40-60% e) [] 20-30%
145. CS. Choose the normal size of the right atrium diameter of the heart: a) [] 20-40 mm b) [] 15 - 20 mm c) [] 40-50 mm d) [] 10 - 20 mm e) [] 50-60 mm

146. CS. Choose the normal size of the left atrium diameter of the heart: a) [] 10 - 20 mm b) [] 15- 20 mm c) [] 20-40 mm d) [] 40-50 mm e) [] 50-60 mm
 147. CM. Indicate the mitral regurgitation causes: a) [] Mitral valve calcification and fibrosis b) [] Rupture of mitral cusp c) [] Cordage rupture d) [] Papillary muscle rupture e) [] Decrease of mitral orifice surface
 148. CM. Select the pathological mechanisms in mitral valvular regurgitation: a) [] Incomplete closure of the mitral cusps b) [] Decrease of mitral orifice surface c) [] Thickening and shortening of chords d) [] Cusps fusion e) [] Inflammatory and sclerotic changes in mitral ring
149. CM. Indicate the changes on heart auscultation in mitral regurgitation: a) [] Sound 1 splitting on apex b) [] Sound 1 is diminished c) [] Systolic murmur at the apex d) [] Diastolic murmur at the apex e) [] Diastolic murmur at aorta
150. CM. Indicate the ECG characteristics of severe mitral regurgitation: a) [] Left atrium hypertrophy b) [] Left deviation of the electric axes of heart c) [] Left ventricule hypertrophie d) [] Atrial fibrillation e) [] Right atrium hypertrophy
151. CM. Indicate the clinical features of mitral regurgitation: a) [] Inspiratory dyspnea on exertion b) [] Palpitations c) [] Cardiac asthma attacks d) [] Syncope e) [] Retrosternal pain on exercise
 152. CM. Choose the pathological changes in mitral stenosis: a) [] Incomplete closure of deformed mitral cusps b) [] Commissural fusion c) [] Thickening and shortening of chords d) [] Cuspal fusion e) [] Inflammatory and sclerotic changes of mitral ring

 153. CM. Indicate the changes to heart auscultation for the mitral stenosis: a) [] Sound 1 is accentuated on apex b) [] Sound 1 is diminished on apex c) [] Systolic murmur on apex d) [] Diastolic murmur on apex e) [] Sound 2 is splitting on apex
154. CM. Choose the ECG signs of mitral stenosis: a) [] Left atrium hypertrophy b) [] Deviation to the left of electrical axis c) [] Right ventricule hypertrophie d) [] Atrial fibrillation e) [] Left ventricule hypertrophie
 155. CM. Indicate the clinical features in mitral stenosis: a) [] Inspiratory dyspnea on exertion b) [] Expiratory dyspnea at rest c) [] Cardiac asthma attacks d) [] Syncope e) [] Retrosternal pain
 156. CM. Choose the correct statements in severe mitral stenosis: a) [] Mitral orifice surface is less than 1.5 cm b) [] Mitral orifice surface is less than 1,0 cm c) [] Mitral orifice surface is less than 2,0 cm d) [] The average pressure in left atrium is above 30 mmHg e) [] Average pressure in left atrium is 20 mmHg
157. CS. Thick the most common cardiomyopathy: a) [] Arrhythmogenic b) [] Dilated c) [] Hypertrophic d) [] Restrictive e) [] Toxic
158. CS. Choose what is mostly involved in dilated cardiomyopathy: a) [] Systolic function b) [] Diastole function c) [] Blood pressure d) [] Pulse e) [] Peripheral resistance
159. CS. Select specific values of ejection fraction in dilated cardiomyopathy: a) [] 70% b) [] 60% c) [] 50% d) [] 100% e) [] 25-39%

 160. CS. Indicate the characteristic changes in dilated cardiomyopathy on echocardiograp a) [] Dilation of all cardiac chambers b) [] Isolated left ventricular dilation c) [] Increase ejection fraction d) [] Isolated right ventricular dilatation e) [] Interventricular septum hypertrophy 	hy:
 161. CS. Choose what is mostly involved in hypertrophic cardiomyopathy: a) [] Systolic function b) [] Diastolic function c) [] Blood pressure d) [] Pulse e) [] Peripheral resistance 	
162. CS. Indicate the characteristic changes in hypertrophic cardiomyopathy on echocardiography: a) [] Dilatation of all cardiac chambers b) [] Left atrial dilation c) [] Increase of ejection fraction d) [] Isolated right ventricular dilatation e) [] Interventricular septum hypertophy	
163. CS. Indicate the morphological changes in restrictive cardiomyopathy: a) [] Diffuse, marked thickening of endocardial and parietal left ventricle, sometimes-right v b) [] Left ventricle hypertrophy c) [] Cardiomegaly d) [] Efilation (thin) of right ventricle walls e) [] Spongy myocardium	entricl
164. CS. Indicate the morphological changes in arrhithmogenic cardiomyopathy: a) [] Diffuse, marked thickening of endocardial and parietal left ventricle, sometimes - right ventricle b) [] Left ventricle hypertrophy c) [] Cardiomegaly d) [] Efilation (thin) of right ventricle walls e) [] Spongy myocardium	
165. CS. Select the cardiomyopathy with favorable prognosis: a) [] Hypertrophic cardiomyopathy b) [] Alcoholic cardiomyopathy c) [] Dilated cardiomyopathy d) [] Restrictive cardiomyopathy e) [] Arrhythmogenic cardiomyopathy	
 166. CM. Indicate hemodynamic changes that occurred in dilated cardiomyopathy: a) [] Decrease of left ventricular ejection fraction b) [] Systolic flow reduction c) [] Increase of heart chamber volumes 	

d) [] Increase of intra cavitary pressuree) [] Increase of ejection fraction
 167. CM. Choose the methods recommended in patients with cardiomyopathy: a) [] Myocardial biopsy b) [] Echocardiography c) [] Phonocardiography d) [] Electrocardiography e) [] ECG monitoring
168. CM. Select the medications used in dilated cardiomyopathy: a) [] Diuretics b) [] ACE inhibitors c) [] Antiarrhythmic d) [] Anticoagulants e) [] Antipyretic
 169. CM. Thick the forms of hypertrophic cardiomyopathy: a) [] Obstructive b) [] No obstructive c) [] Apical d) [] Restrictive e) [] Dilated
 170. CM. Thick the clinical features in hypertrophic cardiomyopathy with outflow tract obstruction: a) [] Inspiratory dyspnea b) [] Exercise independent constrictive retrosternal pain c) [] Syncope d) [] Heart palpitations e) [] Anasarca
171. CM. Select ECG changes in dilated cardiomyopathy: a) [] Left ventricular hypertrophy b) [] Complete left bundle brunch block of His c) [] Atrial fibrillation d) [] Pathological Q-waves e) [] Low QRS voltage
172. CM. Select characteristic ECG changes in hypertrophic cardiomyopathy: a) [] Left ventricular hypertrophy b) [] Increased QRS voltage c) [] Atrial fibrillation d) [] Pathological Q-waves in lower-side leads e) [] Low QRS voltage
173. CM. Indicate the incorrect treatment of patients with obstructive hypertrophic cardiomyopathy: a) [] Cardiac glycosides

b) [] Beta blockers c) [] Nitrates d) [] Diuretics e) [] Antiarrhythmics
174. CM. Thick ECG changes in dilated cardiomyopathy: a) [] Left ventricular hypertrophy b) [] Complete left bundle brunch block of His c) [] Atrial fibrillation d) [] Pathological Q waves e) [] Low QRS voltage
 175. CM. Select surgical methods used in significant obstructive hypertrophic cardiomyopathy a) [] Partial myomectomies b) [] Septal alcohol ablation c) [] First septal embolization d) [] Cardio-verter-defibrillator implantation e) [] Total myomectomies
176. CM. Indicate the ECG changes in dilated cardiomyopathy: a) [] Left ventricular hypertrophy b) [] Complete left bundle brunch block of His c) [] Atrial fibrillation d) [] Pathological Q-waves e) [] Low QRS voltage
177. CM. Select the diseases that can develop restrictive cardiomyopathy: a) [] Endomyocardial fibrosis, eosinophilia (Loffler's syndrome) b) [] Cardiac amyloidosis c) [] Systemic lupus erythematosus d) [] Hemochromatosis e) [] Cardiac lesions by irradiation
178. CM. Indicate the main causes of death in patients with cardiomyopathy: a) [] Atrial fibrillation b) [] Ventriculaire fibrillation c) [] Thromboembolism d) [] Progressive heart failure e) [] Premature heart beats
179. CS. Choose the most common cause of myocarditis: a) [] Viral b) [] Fungal c) [] Toxic d) [] Bacterial e) [] Radiation
180. CS. Choose the most useful and informative method to diagnose myocarditis: a) [] Electrocardiography

 b) [] Echocardiography c) [] Heart X-ray d) [] Coronary angiography e) [] Phonocardiography
181. CS. Select the predominant histological infiltrate in viral myocarditis: a) [] Monocytes b) [] Cells c) [] Eosinophiles d) [] Polymorph nuclear cells e) [] Neutrophils
 182. CS. Indicate the ECG sign of myocarditis: a) [] Absence of P wave b) [] Left and right ventricular hypertrophy c) [] Low QRS voltage d) [] Left and right atrium and hypertrophy e) [] Complete right brunch bundle block of His
183. CS. Indicate the standard diagnostic criteria in myocarditis: a) [] Echocardiography b) [] Endomyocardial biopsy c) [] Coronary angiography d) [] Myocardial scintigraphy with technetium - 99 e) [] Pharmacological test
184. CS. Select the contraindicated medication in acute myocarditis: a) [] Diuretics b) [] Angiotensin converting enzyme inhibitors c) [] Antiarrhythmic medication d) [] NSAIDs e) [] Immunoglobulin
185. CM. Select the main mechanisms of cardiac damage in myocarditis: a) [] Myocardial cell damage caused by invasion of the infection b) [] Immunologically mediated myocardial damage c) [] Direct action of toxins on the myocardium d) [] Sympatoadrenergic mechanism e) [] Neurohormonal activation
186. CM. Indicate the arrhythmias that can be found in myocarditis: a) [] Ccomplete sino atrial block b) [] Ventricular extrasístoles c) [] Atrial tachycardia d) [] Atrial fibrillation e) [] Sinusal tachycardia
187. CM. Select the clinical features of diffuse myocarditis: a) [] Inspiratory dyspnea

 b) [] Fatigability c) [] Palpitations d) [] Sever angina pain e) [] Syncope
188. CM. Indicate the clinical syndromes in myocarditis: a) [] Respiratory failure b) [] Heart failure c) [] Chest pain d) [] Arrhythmias e) [] Abdominal syndrome
 189. CM. Tick the specific cardiac biomarckers for myocarditis: a) [] Creatininfosfokinase -MB b) [] Lactate - izoenzyme I c) [] Troponin I d) [] Alanine aminotransferase e) [] β - lipoproteides
190. CM. Indicate the causes of myocarditis: a) [] Parasites b) [] Fungus c) [] Bacteria d) [] Idiopathic e) [] Autoimmune
191. CM. Select the non-infectious causes of myocarditis: a) [] Autoimmune diseases b) [] Drug hypersensitivity c) [] Toxines d) [] Radiation e) [] Q - fever
192. CM. Indicate the ECG signs in myocarditis: a) [] Decrease of QRS voltage b) [] Cardiac arrhythmias c) [] Heart block d) [] Right ventricular hypertrophy e) [] Right atrium hypertrophy
193. CM. Choose the complication of myocarditis: a) [] Arrhythmias b) [] Conductibility abnormalities c) [] Congestive heart failure d) [] Thromboembolism e) [] Left ventricle aneurysm
194. CM. Select the morphological Dallas criteria of active myocarditis:

a) [] Poor cells infiltration

 b) [] Abundant inflammatory cell infiltration c) [] Myocytes necrosis d) [] Myocytes hipertrophy e) [] Myocytes degeneration
 195. CM. Indicate the laboratory abnormalities in myocarditis: a) [] B-12 deficient anemia b) [] Hight C -reactive protein c) [] Presence of circulating immune complexes d) [] Increase of myocardial biomarkers e) [] Hypochromic anemia
 196. CM. Tick the medications used in acute staphylococcal myocarditis treatment: a) [] Diuretics b) [] Inhibitors of converting angiotensin II enzyme c) [] Immunoglobulin d) [] Antiarrhythmic e) [] Corticosteroids
197. CM. Choose the drugs that may increase viral replication in acute myocarditis: a) [] Corticosteroids b) [] Anti-inflammatory drugs c) [] Antibiotics d) [] Antiarrhythmic e) [] Diuretics
198. CM. Choose the medications recommended in myocarditis with congestive heart failure: a) [] Diuretics b) [] Corticosteroids c) [] Glycosides d) [] Inhibitors of converting angiotensin II enzyme e) [] Vitamins
 199. CS. Indicate the most common type of syncope: a) [] Orthostatic hypotension b) [] Cardiac arrhythmias c) [] Neurogenic mediated d) [] Structural cardiopulmonary diseases e) [] Syncope of unknown origin
 200. CS. Select the condition of neurogenic mediated syncope: a) [] Prolonged standing b) [] Low blood pressure c) [] Diabetes d) [] Traumatic disorders of the spinal cord e) [] Cardiac arrhythmias
201. CS. Indicate the condition of the situational syncope: a) [] Primary autonomic failure

 b) [] Secondary autonomic failure c) [] Produced by gastrointestinal stimulation, urination, weight lifting d) [] Occurs without triggers e) [] Hypovolemia (bleeding, diarrhea, vomiting)
 202. CS. Indicate the correct statement about orthostatic hypotension: a) [] Sudden reduction of the blood pressure in standing with over 40 mmHg b) [] Progressive decrease of the systolic blood pressure in standing c) [] Sinus tachycardia with the heart rate over 120 bpm (at least 30 bpm above the resting rate) d) [] Decrease of the systolic blood pressure by at least 20 mmHg and diastolic blood pressure by at least 10 mmHg within 3 min of stand up e) [] Occurs in situations of chronic fatigue syndrome
 203. CS. Indicate the drug that may cause orthostatic hypotension: a) [] Anticoagulants b) [] Diuretics c) [] Antiarrhythmic d) [] Antidiuretics e) [] NSAIDs
 204. CS. Indicate the groups were orthostatic hypotension is more frequently: a) [] Adult population b) [] Elderly patients c) [] Young women d) [] Adolescents e) [] Young men
 205. CS. Indicate the correct statement about sinus carotid hypersensitivity syncope: a) [] Occurs sudden by movement of the head, closely tie knot b) [] Produced by swallowing, defecation, visceral pain c) [] Occurs by emotional stress d) [] Occurs by instrumental manipulations e) [] Occurs during or immediately after the swallowing
 206. CS. Select the most common causes of cardiac syncope: a) [] Hypovolemia b) [] Structural heart disease c) [] Conductibility and rhythm disorders d) [] Pulmonary valve stenosis e) [] Aortic dissection
207. CS. Indicate the main method in the diagnosis of cardiac syncope: a) [] Eco-Doppler b) [] Electrocardiogram c) [] Chest X-ray d) [] Tilt table test e) [] Coronary angiography

208. CS. Indicate the most common type of syncope:

 a) [] Reflex mediated syncope b) [] Syncope caused by structural heart disease c) [] Orthostatic hypotension d) [] Cardiac syncope caused by arrhythmias e) [] The hypersensitivity syndrome of the carotid sinus
 209. CM. Mark the suspicious clinical signs for a cardiac syncope: a) [] Presence of organic heart pathology b) [] Onset with exertion or supine c) [] Palpitations during syncope d) [] Nauseas e) [] Dizziness
 210. CM. Indicate the suspicious clinical signs for a nonsyncope fall: a) [] Presence of post-critical disorientation b) [] Tonic-clonic seizures during attack c) [] Multiple somatic complaints and hits without organic heart damage d) [] Association of fall with palpitation e) [] Association of fall with dysarthria, diplopia
 211. CM. Select the suspicious ECG signs of cardiac syncope: a) [] Left atrial hypertrophy b) [] AV block II degree c) [] Sinus bradycardia <50 bpm d) [] Wolf Parkinson White syndrome e) [] Prolonged QT
212. CM. Choose the factors that predicts rhythm disorder as a cause of syncope: a) [] Heart rate too low b) [] Heart rate too quick c) [] Normal ejection fraction d) [] Low ejection fraction e) [] Ventricular arrhythmia
213. CM. Indicate the structural heart diseases that cause syncope: a) [] Mitral regurgitation b) [] Hypertrophic cardiomyopathy c) [] Aortic stenosis d) [] Mitral stenosis e) [] Supraventricular extrasystolies
214. CM. Indicate the tests for differential diagnosis of syncope: a) [] Carotid sinus massage b) [] Tilt-test c) [] Holter-ECG monitoring d) [] Electrophysiological studies e) [] Ambulatory blood pressure monitoring
215. CM. Choose the methods for evaluation of neurogenic mediated syncope:

 a) [] Carotid sinus massage b) [] Echocardiography c) [] ECG term monitoring (Holter, implantable devices) d) [] Electrophysiological studies e) [] Tilt-test
216. CM. Indicate criteria for positive carotid sinus massage test: a) [] Asystole > 3 sec and/or decrease of systolic blood pressure > 50 mm from initial level b) [] Suggestive clinical symptoms c) [] Presence of post-critical disorientation d) [] Increase of the blood pressure e) [] Palpitations during the test
 217. CM. Choose the tests non-informative diagnostic in evaluating syncope: a) [] Tilt-test b) [] ECG monitoring c) [] Electroencephalography d) [] Magnetic Resonance Imaging e) [] Computer tomography of brain
 218. CM. Diagnostic criteria for neurogenic mediated syncope are: a) [] Lack of cardiac pathology b) [] Presents of cardiac pathology c) [] Onset after emotions, finding long in crowded places, prolonged orthostatic d) [] Nausea, lightheadedness before syncope e) [] Occurred in 1 hour after eating
 219. CM. Select the correct statements in performing of carotid sinus massage: a) [] Age > 40 years b) [] Unidentified cause of syncope (after initial assessment) c) [] It performs during exertion d) [] It performs supine position / standing e) [] It is performed under ECG monitoring, blood pressure for 5-10sec
 220. CM. Choose the true statements for Tilt - test: a) [] Recommended in syncope with unidentified genesis b) [] It is performed in patients with intact heart c) [] Positive test is considered the diagnosis for the vasovagal syncope d) [] Positive test is loss of consciousness with induction of hypertension e) [] Positive test is loss of consciousness with induction of tachycardia
221. CM. Indicate what require complete evaluation of a patient with syncope: a) [] Neurological evaluation b) [] Psychiatric evaluation c) [] Coronary angiography d) [] Pharmacological tests e) [] Electrophysiological study

222. CM. Select criteria for hospitalization in patient with syncope:

 a) [] Suspicious of cardiac syncope b) [] Syncope is followed by a severe trauma c) [] Rare syncope without risk factors d) [] Single syncope episode e) [] Syncope with high recurrence
 223. CM. Indicate criteria for treatment in patients with syncope: a) [] Single syncope episodes without risk factors b) [] Frequent syncope that affect the quality of life c) [] Syncope without exposure to the trauma d) [] High-risk professional activities (driving cars, machine operators, drivers and others) e) [] Arrhythmic syncope with vital risk
224. CM. Select the true statements about cardiac syncope: a) [] Electrical cardiac stimulator implantation prevents the recurrence of syncope in patients with heart block b) [] Implantation of the electrical cardiac stimulator decreases the survival c) [] Implantation of the electrical cardiac stimulator will be considered in all patients with branch bundle block d) [] Ventricular tachycardia is suspected as a cause of syncope in patients with left ventricular dysfunction e) [] Supraventricular tachycardia is suspected as a cause of syncope in patients with left ventricular dysfunction
 225. CM. Choose indications for tilt - table test? a) [] Syncope in patients with organic structural heart diseases b) [] Undifferentiated syncope with a high risk of trauma c) [] To differentiate vaso-vagal syncope and orthostatic hypotension d) [] To confirm arrithmogenic syncope e) [] Is indicated for the assessment of treatment
 226. CM. Select correct statements about pharmacological tilt - table test: a) [] Highly specificity (more than 90%) b) [] It is performed with dopamine intravenous c) [] It is used with isoproterenol intravenous d) [] It is used sublingual nitroglycerin e) [] It is performed 20 minutes after the base phase of the test
227. CM. Mention the indications for electrophysiological studies in patients with syncope: a) [] Reflex syncope b) [] Suggesting an arrhythmia as the cause of a syncope c) [] Palpitations precede syncope d) [] Brugada syndrome e) [] Patients with arrhythmogenic right ventricular cardiomyopathy
228. CM. Select correct statements about syncope in elderly: a) [] Syncope is more common than in the general population b) [] Rapid atrial fibrillation is a causal factor for the syncope in elderly c) [] Diuretics may cause syncope

d) [] Statins can cause syncopee) [] Neurological diseases can cause syncope
 229. CS. Indicate the clinical sign that is NOT characteristic for the sudden cardiac death: a) [] It is natural death b) [] Death from cardiac disease c) [] The sudden loss of consciousness d) [] Occurs within one hour of the onset of acute symptoms e) [] Occurs within two hours after the onset of acute symptoms
230. CS. Indicate the EXCEPT element from definition of the sudden cardiac death: a) [] Prodromal b) [] The onset of the final event c) [] Respiratory failure d) [] Cardiac arrest e) [] Biological death
 231. CS. Select the EXCEPT for the biological death: a) [] It is an immediate consequence of cardiac arrest b) [] It is the failure of resuscitation c) [] It is the absence of mechanical, electrical heart activity and central nervous system after the resuscitation d) [] It is only the absence of mechanical, electrical activity of the heart after the resuscitation e) [] Usually occurs within some minutes after the cardiac arrest
 232. CS. Choose the precursory symptoms of cardiac sudden death: a) [] Often are absent and nonspecific b) [] Often are well expressed and specific c) [] Have an insidious onset d) [] Don't lead to cardiac imminent arrest e) [] Occur in an interval longer than one hour
233. CS. Select correct statement for the sudden cardiac death: a) [] It constitutes approximately 60% of all deaths from cardiac cause b) [] It constitutes approximately 75% of all deaths from cardiac cause c) [] It constitutes approximately 65% of all deaths from cardiac cause d) [] It constitutes approximately 50% of all deaths from cardiac cause e) [] It constitutes approximately 80% of all deaths from cardiac cause
 234. CS. Tick the correct statement about sudden cardiac death: a) [] It is more common in males b) [] It is more common in females c) [] It has the same frequency in both sexes d) [] It is more common in the elderly e) [] It increases progressively in young people
 235. CS. Indicate incorrect statement about sudden cardiac death: a) [] Prevalence by age group has two peaks b) [] High prevalence in the newborn period

 c) [] High prevalence in the elderly d) [] In recent years gradually increase the proportion of women who die suddenly e) [] It increases progressively the proportion of young people who die suddenly
236. CS. Select incorrect risk factors for sudden cardiac death: a) [] Myocardial ischemia b) [] Hypertension c) [] Smoking d) [] Obesity e) [] Mitral valve prolapse
237. CS. Mention the most frequent cause for the sudden cardiac death: a) [] Cardiomyopathies b) [] Rheumatic heart diseases c) [] Coronary atherosclerotic diseases d) [] Inflammatory heart diseases e) [] Congenital heart diseases
 238. CS. Indicate the most important predictor of sudden cardiac death: a) [] Diabetes mellitus b) [] The elongation of the ventricular repolarization c) [] Severe left ventricular systolic dysfunction (EF <35%) d) [] Low social economical status e) [] Genetics
239. CS. Indicate the elements causes the electrical abnormalities in patients with sudden cardiac death: a) [] Scar zones b) [] Left ventricular hypertrophy c) [] Cracked plaque d) [] Structurally normal heart e) [] Occlusive thrombus
240. CS. Select INCORRECT statement about risk for sudden cardiac death in diabetes mellitus patients: a) [] Presence of accelerated forms of atherosclerosis b) [] Increase of the thrombogenity c) [] Diabetic cardiomyopathy d) [] QT prolongation e) [] Association with mitral valve prolapse
241. CM. Choose EXCEPT element in the diagnosis of sudden cardiac death: a) [] Traumatic character b) [] The natural character (non-traumatic) c) [] Rapid (within 1 hour) d) [] Insidious e) [] Unexpected (sudden)

242. CM. Indicate the tachyarrhythmia's that can cause sudden cardiac death:

 a) [] Electromechanical dissociation b) [] Ventricular fibrillation c) [] Idioventricular rhythm d) [] Bradycardia e) [] Sustained ventricular tachycardia
243. CM. Mention the pathologies that can cause sudden cardiac death: a) [] Hypertrophic cardiomyopathy b) [] Hypertension c) [] Brugada syndrome d) [] Mitral regurgitation e) [] Myocardial bridges
 244. CM. Indicate the mechanisms of electrical instability contribute to sudden cardiac death: a) [] Acute ischemia with the production of the electrical faults in the myocardium b) [] Increased oxygen consumption in the presence of a significant coronary stenosis c) [] Diffuse myocardial metabolic abnormalities d) [] Stable angina pectoris e) [] Myocardial infarction scars and appearance of the reentrant circuits
 245. CM. Indicate the three classes of sudden cardiac death according Hinkle classification: a) [] Sudden arrhythmogenic death b) [] Occurrence of the ventricular ectopies c) [] Sudden death with circulatory failure d) [] Sudden death without stating the cause e) [] Installation of cardiac arrest
246. CM. Indicate the pathology that can be identified in ischemic heart disease in patients with sudden cardiac death: a) [] Scar zones b) [] Left ventricular hypertrophy c) [] Cracked atheroma plaques d) [] Structurally normal heart e) [] Occlusive thrombus
247. CM. Mention the prodromal symptoms of sudden cardiac death: a) [] Chest pain b) [] Dyspnea c) [] Cough d) [] Palpitations e) [] Syncope
 248. CM. Indicate correct statements for event in the onset of sudden cardiac death: a) [] Installation of hypertension b) [] Slow changes of the clinical status c) [] Dynamic changes in the electrical activity of the heart d) [] Occurrence of malignant ventricular arrhythmias e) [] Installation of the cardiac arrest

 249. CM. Select the characteristics of the cardiac arrest: a) [] Sudden stop of the pump function that quickly leads to death b) [] Increase of cerebral flow c) [] Effective circulation d) [] Hypotension e) [] Syncope
 250. CM. Indicate the interval of time that irreversible brain damages occur: a) [] After 4-6 minutes from the stopping of the cerebral circulation in the absence of any intervention b) [] After 8 minutes after application of basal life support c) [] 20 minutes after application of basal life support d) [] After 20 minutes from the stop of the cerebral circulation in the absence of any intervention e) [] About 16 min if advanced resuscitation measures are applied
 251. CM. Thick the characteristic signs of sudden cardiac death: a) [] Gradual breathing stop - "mirror sign" b) [] Absence of pulse on carotid vessels c) [] Dyspnea d) [] Loss of consciousness e) [] Mydriasis (2-3 minutes)
252. CM. Choose the cardiac causes of the sudden cardiac death in children: a) [] Idiopathic ventricular fibrillation b) [] Congenital QT syndrome c) [] Bleeding d) [] Myocarditis e) [] Asthma access
253. CM. Indicate the non-cardiac causes of sudden death in children: a) [] Idiopathic ventricular fibrillation b) [] Congenital QT syndrome c) [] Bleeding d) [] Poisoning e) [] Asthma access
254. CM. Indicate the non-invasive methods in assessment of patients with a risk for sudden cardiac death. a) [] Electrophysiological tests b) [] EcoCG - Doppler c) [] ECG d) [] CT heart e) [] Cardiac catheterization
255. CM. Select the invasive methods in assessment of patients with a risk for sudden cardiac death a) [] Electrophysiological tests b) [] ECoCG-Doppler c) [] Coronary angiography

d) [] Scheduled stimulatione) [] Cardiac catheterization
256. CM. Indicate the ECG signs in patients with increased risk of sudden cardiac death: a) [] Short QT interval b) [] Left ventricular hypertrophy c) [] Long QT interval d) [] Brugada syndrome e) [] Left and right atrium hypertrophy
 257. CM. Choose the relevant data detected by Eco-CG Doppler in patients with high risk of sudden cardiac death: a) [] Ejection fraction <30-35% b) [] Ejection fraction ≥35% c) [] Negative T wave d) [] Tricuspid regurgitation e) [] Sever aortic stenosis
258. CM. Select the indication for Holter ECG monitoring in patients with risk of sudden cardiac death: a) [] Ventricular arrhythmias b) [] Impaired left ventricular function c) [] Hypertrophic cardiomyopathy d) [] The assessment of ventricular brady arrhythmias e) [] Syncope
259. CS. Indicate the age in which about 83% of the population is affected by coronary heart disease: a) [] 45 years b) [] 35 years c) [] 65 years d) [] 85 years e) [] 70 years
 260. CS. Select the correct definition of the body mass index: a) [] Circumference measured from the umbilicus and halfway between the costal margin and iliac crest b) [] The ratio of weight (kg) and the square of the height (m) c) [] Report of the 2 circumferences reflects the type of obesity d) [] LDL cholesterol and HDL cholesterol ratio e) [] Report of 3 circumferences reflects the type of obesity
 261. CS. Chose the definition of the obesity paradox: a) [] Growing problem in the developed world b) [] It is a major risk factor for atherosclerotic disease c) [] A better short or long-term prognosis for overweight or obese patients d) [] It is a minor risk factor for atherosclerotic disease e) [] A poor short or long-term prognosis for overweight or obese patients

268. CM. Choose correct statements about major risk factors defined by Word Health Organization:

 a) [] High prevalence in the population b) [] Low prevalence in the population c) [] Independent impact on the risk of coronary heart disease or stroke d) [] Treatment or control lowers the risk e) [] Treatment or control risk-accelerating
269. CM. Tick the cardiovascular risk factors that are considered unmodifiable: a) [] Obesity b) [] Age c) [] High blood pressure d) [] Sex e) [] Family history
270. CM. Indicate the factors which increase prevalence of obesity as a major cardiovascular risk factor: a) [] Social factors b) [] Dietary habits c) [] Hypertension d) [] Alcohol abuse e) [] Lack of physical activity
271. CM. Indicate the difference between SCORE and Framingham score: a) [] SCORE assess only the risk of cardiovascular mortality b) [] Assessment of SCORE includes diabetes c) [] Assessment of SCORE includes HDL-cholesterol d) [] Assessment of SCORE includes total cholesterol e) [] SCORE assess the risk for cardiovascular events
 272. CM. Choose the correct statements about dyslipidemia: a) [] Great prevalence and susceptibility of being modified b) [] It is one of the factors with low prevalence and susceptibility of being modified c) [] Is related to cardiovascular mortality and total cardiovascular events d) [] Has better short or long-term prognosis for overweight and obese patients e) [] Includes a number of disorders of lipid metabolism potentially induction of atherosclerosis
273. CM. Indicate the components included in the cardiovascular prevention according to the World Health Organization: a) [] Family strategy b) [] Population strategy c) [] Strategy for high-risk populations d) [] Secondary prevention e) [] Strategy for low risk populations
 274. CM. Choose the characteristics of individuals with high cardiovascular risk: a) [] Multiple risk factors, giving a risk score ≥ 5% b) [] Marked increased level of a single risk factor, such as BP ≥ 180/110 mmHg c) [] Total cholesterol ≥ 5 mmol/L d) [] Presents of diabetes mellitus e) [] Multiple risk factors, giving a risk score > 3%

275. CM. Indicate the correct statements about chart SCORE: a) [] Assess the risk of fatal cardiovascular event within 10 years b) [] Assess the risk of fatal cardiovascular event within 5 years c) [] Assess the impact of non-traditional risk factors d) [] Estimate the absolute risk of death in the same age group e) [] Highlights the effect of the action of a risk factor over time
 276. CM. Tick the factors of hemostasis which correlate with increased cardiovascular risk: a) [] Activated factor VII b) [] Plasminogen activator inhibitor-1 c) [] Activated factor V d) [] Tissue plasminogen activator e) [] Von Willebrand factor
277. CM. Indicate the lifestyle changes which reduce cardiovascular risk in hypertension: a) [] High sodium diet, low weight, moderate consumption of ethyl alcohols b) [] Low sodium diet, low weight, moderate consumption of ethyl alcohols c) [] Regular physical activity d) [] Limitation of physical activity e) [] An optimal control of blood pressure values
278. CM. Choose the mechanisms which increase cardiovascular risk in smoking: a) [] Increased total cholesterol and lower HDL cholesterol b) [] Increasing of circular fibrinogen c) [] Decreasing of circular fibrinogen d) [] Arterial vasodilation e) [] Increasing heart rate and blood pressure
279. CS. Choose which of the markers listed below refers to the injury of myocytes: a) [] C-reactive protein b) [] Norepinephrine c) [] Angiotensin II d) [] Oxidized low-density lipoproteins e) [] Troponins I and T
280. CS. Choose, which set of the markers listed below, refers to those of inflammation: a) [] C-reactive protein tumor necrosis factor alpha, interleukins, Fas (APO1) b) [] Norepinephrine, epinephrine, angiotensin II, renin, aldosterone, arginine vasopressin, endothelin c) [] B- natriuretic peptide (BNP), NTpro-BNP, proadrenomedulina d) [] Oxidized low-density lipoproteins, myeloperoxidases, malondialdehyde, urinary biopirines e) [] Troponins T, creatine kinase MB, light chain myosin kinase, cardiac fatty acids
281. CS. Choose, which set of the markers listed below, refers to those of oxidative stress: a) [] C-reactive protein, tumor necrosis factor alpha, interleukins, Fas (APO1) b) [] Norepinephrine, epinephrine, angiotensin II, renin, aldosterone, arginine vasopressin, endothelin c) [] B- natriuretic peptide (BNP), NTpro-BNP, proadrenomedulina

d) [] Oxidized low-density lipoproteins, myeloperoxidases, malondialdehyde, urinary biopirinese) [] Troponins T, creatine kinase MB, light chain myosin kinase, cardiac fatty acids
282. CS. Choose, which set of the markers listed below, refers to neurohormonal ones: a) [] C-reactive protein, tumor necrosis factor alpha, interleukins, Fas (APO1) b) [] Norepinephrine, epinephrine, angiotensin II, renin, aldosterone, arginine vasopressin, endothelin c) [] B- natriuretic peptide (BNP), NTpro-BNP, proadrenomeduline d) [] Oxidized low-density lipoproteins, myeloperoxidases, malondialdehyde, urinary biopirines e) [] Troponins T, creatine kinase MB, light chain myosin kinase, cardiac fatty acids
 283. CS. Choose which of the biomarkers refers to the stress of myocytes: a) [] Tumor necrosis factor alpha b) [] Angiotensin II c) [] B - natriuretic peptide d) [] Myeloperoxidases e) [] Creatine kinase - MB
 284. CS. Indicate the correct statements about continuous ECG monitoring: a) [] Recommended for patients with hypertension b) [] Particularly useful in symptomatic patients with intermittent symptoms occurring daily or almost daily c) [] The most used method for the diagnosis of unstable angina d) [] Provides information about pulmonary circulation and thoracic aorta e) [] The most used method for the diagnosis of acute myocardial infarction
285. CS. Indicate the correct statements about intermittent ECG monitoring are: a) [] Recommended for patients with sporadic symptoms able to activate the device immediately b) [] Particularly useful in symptomatic patients with intermittent symptoms occurring daily or almost daily c) [] The most used method for the diagnosis of unstable angina d) [] Provides information about pulmonary circulation and thoracic aorta e) [] The most used method for the diagnosis of acute myocardial infarction
286. CS. Thick the correct value of resting potential of cardiomyocytes: a) []-70mV b) []+40mV c) []-90mV d) [] 0 mV e) []+10 mV
287. CS. Choose how many derivations are used to record standard ECG: a) [] 10 derivation b) [] 12 derivations c) [] 6 derivations d) [] 8 derivations e) [] 2 derivations

288. CS. Indicate what show the enlargement of the right atrium on radiography:

 a) [] Opacity of retrosternal space b) [] Bulging lower arch as more than 5.5 cm to the right of the midline c) [] Previous projection of thoracic vertebral bodies d) [] Opacity of sub diaphragmatic space e) [] Diffuse opacity
289. CS. Select the FALSE statement regarding pulsed Doppler: a) [] It measures blood velocity in the direction of the ultrasound beam b) [] It has a low amplitude measurable velocity c) [] It measures blood velocity only in the interest zone d) [] It is destinated for flows with low velocity e) [] It has a spatial resolution
290. CS. Indicate the EXEPT advantage of radionuclide ventriculography over radiological ventriculography with contrast: a) [] The test provides detailed information on the anatomy of the cardiac chambers and valvular function b) [] The ability to study both ventricles simultaneously c) [] Ability to take repeated measurements (before and after exercise) d) [] The method provides optimum contrast between target ventricular volumes and backgrounde) [] Noninvasive nuclear procedures
291. CS. Indicate the EXEPT situation for ECG exercise test cessation: a) [] Decrease of systolic blood pressure over 10 mm Hg from baseline b) [] Hiccup c) [] Moderate/severe angina pain d) [] Dizziness, ataxia or presyncope e) [] Cyanosis or pallor of skin
292. CS. Select the correct distance of thoracic X-ray examination in posterior-anterior incidence: a) [] 1,5-2 m b) [] 30-50 cm c) [] 1 m d) [] 20-25 cm e) [] 2-3 m
 293. CS. Indicate the correct statements about ECG at rest: a) [] It is the most used method in the diagnosis of stable angina b) [] It is a noninvasive method most commonly used in cardiological examination c) [] It is used to assess heart structures and its chambers d) [] Provides information about pulmonary circulation and thoracic aorta e) [] Allows continuous monitoring of heart disease
294. CS. Select which IS NOT characteristic for positron emission tomography: a) [] It is indicated in patients with hypo perfused and dysfunctional myocardial segments b) [] It is indicated in metabolic syndrome c) [] It is used to detect microcirculation dysfunction d) [] It is used to determine the coronary calcium score.

e) [] It is ECG based method
295. CS. Select the general diagnostic accuracy of positron emission tomography study: a) [] 90 % b) [] 60% c) [] 100% d) [] 75% e) [] 40%
296. CS. Indicate the most used score to determine coronary calcium score: a) [] Mobitz score b) [] Hounsfield score c) [] Agatston score d) [] Sokolow score e) [] Hoffman score
 297. CS. Indicate what IS NOT characteristic for balanced radionucleide ventriculography: a) [] Assume the purchase of 16-24 frames in RR interval b) [] It is records a short sequence of cardiac cycles c) [] In balanced radionuclide ventriculography labeled 99mTc red blood cells are used d) [] Balanced radionuclide ventriculography synchronized requires the presence of sinus rhythm e) [] Data are acquired sequentially in the memory of a proper frame
298. CS. Select what ECG exercise testing included: a) [] Administration of Dipiridamole b) [] Tilted table c) [] Cycling or treadmill d) [] Administration of Ergometrine e) [] Respiratory exercises
299. CS. Mention what is the intracardiac electrophysiological study: a) [] Noninvasive diagnostic method of cardiac rhythm disorders b) [] Invasive diagnostic method of cardiac rhythm disorders and management of cardiac arrhythmias c) [] Study of cardiac activity using 3D Eco d) [] Exclusive diagnostics of atrial and ventricular fibrillation e) [] Method of testing only in elderly patients
300. CS. Indicate the most often used way of approach for introducing catheters in electrophysiological study: a) [] Vena saphena magna b) [] Fémorale veine c) [] Abdominal aorta d) [] Inferior vena cava e) [] Femoral artery
 301. CS. Choose the radiological sign of ascending aorta dilation: a) [] A prominent aortic button b) [] Difficult to assess

 c) [] Curved upper right arc d) [] Curved arc left upper e) [] Not changes on radiography
302. CS. Indicate the X-ray characteristic of the pulmonary venous hypertensions: a) [] Vessels in the upper lung fields are equal to or greater than the basal b) [] Vessels in the upper lung fields are equal to or less than the basal c) [] Vessels in the upper lung fields become equal to the basal d) [] Dilatation of the pulmonary artery trunk e) [] Spasm of central vessels
 303. CS. Choose the NOT characteristic X-ray aspects of interstitial pulmonary edema: a) [] The opaque pleural axillary or basal tape b) [] Changes in heart consideration c) [] The inelar opacity d) [] Left atrium increase e) [] Alveolar transudation as nodular opacity, localized mainly at the base
 304. CS. Choose the definition of cardiac biomarkers sensitivity: a) [] The power to identify real negative cases b) [] The ability to detect true positive cases c) [] Ability to identify a single disease d) [] Presence of instable marker in the body e) [] The vulnerability of the marker to the action of environmental factors
305. CS. Choose the definition of specificity of cardiac biomarkers: a) [] The ability to detect true positive cases b) [] The vulnerability of the marker to the action of environmental factors c) [] Ability to identify a single disease d) [] The power to identify real negative cases e) [] Presence of instable marker in the body
306. CS. Indicate what the left middle arch on thoracic radiography is: a) [] Ascending aorta b) [] Pulmonary trunk c) [] Descending aorta d) [] Left atrium e) [] Left ventricle
307. CS. Mention what is necessary to introduce in intracavitary ventriculography: a) [] Foley Catheter b) [] Catheter "Pigtail" c) [] Sleep probe d) [] Probe Swan-Ganz e) [] Judkins catheter
308. CS. Tick the NOT frequent complications of cardiac catheterization and angiography: a) [] Hematoma at puncture site b) [] Vasovagal reactions

 c) [] Allergic reactions to contrast agents and drugs d) [] Inflammation or exudate at puncture site e) [] Trauma
309. CM. Select the biomarkers related to of myocytes injury: a) [] Troponin I and T b) [] Cardiac fatty acids bound to protein c) [] Creatine kinase - MB d) [] Albumin modified by ischemia e) [] Interleukins 1, 6
310. CM. Select the biomarkers related to interstitial remodeling matrix: a) [] Myosin - light chain kinase b) [] C-reactive protein c) [] Matrix metalloproteinase d) [] Tissue inhibitors of metalloproteinase e) [] Peptide procollagen I
311. CM. Select the biomarkers related to inflammation: a) [] Albumin modified by ischemia b) [] C-reactive protein c) [] Tumor necrosis factor alpha d) [] Fas (APO-1) e) [] Interleukins 1, 6 and 8
312. CM. Select the biomarkers related to oxidative stress: a) [] Oxidized low density lipoprotein b) [] Mielloproteases c) [] Melondialdehyde d) [] C-reactive protein e) [] Tumor necrosis factor alpha
313. CM. Select the biomarkers related to neuroumoral abnormalities: a) [] Peptide heart natriuretic b) [] Renin - angiotensin-aldosterone c) [] Adrenergic nervous system d) [] Arginine vasopressin e) [] Mielloproteases
314. CM. Indicate the suggesting diagnosis provided by ECG: a) [] Acute Coronary Syndrome b) [] Arrhythmias c) [] Dilated cardiomyopathy d) [] Conductibility disorders e) [] Dis electrolytemia
315. CM. Select the indications to the standard 12 leads electrocardiogram in cardiology practice: a) [] Assessment of the side effects of treatment

 b) [] Regularly evaluation of chronic heart disease c) [] Evaluation of patients with increased risk of cardiovascular d) [] Routine examinations of patients > 40 years old e) [] Routine examinations of patients > 60 years old
316. CM. Indicate the correct statements about left ventricular hypertrophy: a) [] ST segment elevation on ECG b) [] It is an independent prognostic parameter value c) [] It is important for risk stratification in hypertensive patients d) [] Lower sensitivity of ECG compared to echocardiography e) [] No changes on ECG
 317. CM. Select what condition can influence quality of ECG: a) [] Chronic lung disease b) [] Incorrect placement of electrodes c) [] Obesity d) [] Renal involvement e) [] Respiratory movements
318. CM. Select the indications to standard 12-lead electrocardiogram: a) [] Pacemaker implant b) [] Increased risk of heart disease c) [] Stable chronic heart disease d) [] Patients aged >40 during a routine examination e) [] Acute respiratory impairment
319. CM. Thick the main ECG criteria for diagnosis of left ventricular hypertrophy: a) [] Sokolow-Lyon b) [] Duck c) [] Wenckebah d) [] Cornell e) [] Mobitz
320. CM. Select the absolute contraindications for ECG stress test: a) [] Acute aortic dissection b) [] Headache c) [] Physical or mental disorders d) [] Myocardial infarction (within 2 days after onset) e) [] Acute pulmonary embolism
321. CM. Indicate what is used for perfusion in imaging: a) [] Technetium 99 b) [] Vasovist c) [] Thallium 201 d) [] TESLASCAN e) [] BaSO4
322. CM. Choose what includes radionuclide imaging in cardiology: a) [] Myocardial perfusion scintigram

 b) [] Radionuclide ventriculography c) [] ECG Holter d) [] Positron emission tomography e) [] Ergometry
 323. CM. Select the indication for transesophageal echocardiography: a) [] Detection of small vegetation in infective endocarditis b) [] Detecting of sources of embolism c) [] Evaluation of congenital heart disease d) [] Evaluation of aortic prostheses e) [] Hypertension
 324. CM. Mention the contrast agents used in CT examination in cardiology: a) [] Silicon b) [] OMNIPAQUE c) [] Visipaque d) [] Technetium e) [] Ultravist
325. CM. Tick the physiological limitations of CT investigation: a) [] The presence of arrhythmias b) [] Sinus tachycardia c) [] The presence of calcifications d) [] The cost of the contrast e) [] Irradiance dose
326. CM. Select what magnetic resonance imaging allows diagnosing: a) [] Hypertension b) [] Myocarditis c) [] Cardiomyopathy d) [] Valvulopathy e) [] Angina pectoris
 327. CM. Indicate the main indications for ambulatory ECG monitoring: a) [] Unexplained palpitations b) [] Assessment of antiarrhythmic therapy c) [] Cardiac tamponade d) [] Pericardial effusion e) [] Patients with unexplained syncope
328. CM. Choose the X ray characteristics of arterial pulmonary hypertension: a) [] Vessels in the upper lung fields are equal to or greater than the basal b) [] Vessels in the upper lung fields are equal to or less than the basal c) [] Vessels in the upper lung fields become equal to the basal d) [] Dilatation of the pulmonary artery trunk e) [] Pulmonary hilum is large due to much dilate central vessels compared with peripheral ones
329. CM. Indicate echocardiography advantages: a) [] It provides accurate information about structure and function of the heart

 b) [] It is widely available c) [] It is easily repeatable if necessary d) [] It is invasive method e) [] It is cost-effective
 330. CM. Select the main methods used for routine echocardiography: a) [] Echocardiography in M regime b) [] Trans esophageal echocardiography c) [] 2D echocardiography (two-dimensional) d) [] Doppler echocardiography e) [] 3D echocardiography
331. CM. Mention which of the following should be determined to assess pulmonary circulation: a) [] Right pulmonary diameter b) [] Distribution of pulmonary circulation c) [] Spirography results d) [] It can't be appreciated e) [] Diameter of aorta
332. CM. Select types of potential serological biomarkers present in cardiovascular disease: a) [] Myocytes injury markers b) [] Markers of inflammation c) [] Oxidative stress markers d) [] Electric markers e) [] Psychological stress markers
333. CM. Choose the myocyte injury markers: a) [] C-reactive protein b) [] Troponin I and T c) [] Myosin light chain kinase d) [] Malondialdehyde e) [] B natriuretic peptide
334. CM. Choose myocyte stress markers: a) [] B natriuretic peptide b) [] Malondialdehyde c) [] Proadrenomedulina d) [] Troponin I and T e) [] Interleukins
 335. CS. Indicate complication of chronic renal failure: a) [] Hypertrophic cardiomyopathy b) [] Uremic pericarditis c) [] Angina pectoris d) [] Myocarditis e) [] Valvular heart disease
336. CS. Select the group of drug used in treatment of viral pericarditis: a) [] Antibiotics

 b) [] Non-steroidal anti-inflammatory drugs c) [] Chemotherapy d) [] b-blockers e) [] Antifungal
337. CS. Thick the most important auscultation feature in constrictive pericarditis: a) [] Noise of a falling drop b) [] Diastolic clacment c) [] Gallop rhythm d) [] Systolic blast e) [] Noise II in place of aortic valve auscultation
 338. CS. Tick the cause of cardiac tamponade: a) [] Basal pneumonia b) [] Mitral insufficiency c) [] Uremia d) [] Hypertension e) [] Ventricular paroxysmal tachycardia
 339. CS. Tick the group of drugs used in the treatment of septic pericarditis: a) [] Antibiotics b) [] Diuretics c) [] Analgesics d) [] Antihypertensive e) [] Diuretics
340. CS. Indicate EXCEPT form of pericarditis: a) [] Post myocardial infarction b) [] Uremic c) [] Pre myocardial infarction d) [] Post irradiation e) [] Tuberculosis
341. CS. Mention the EXCEPTION viral disease as cause of infectious pericarditis: a) [] Endemic mumps b) [] Varicella c) [] AIDS d) [] Viral meningitis e) [] Infectious mononucleosis
342. CS. Indicate the ECG characteristic of III stage acute pericarditis: a) [] Negative T waves in I, II, aVL b) [] Negative T waves in aVR, V1, V2 c) [] ST segment depression in aVR, V1, V2 d) [] ST segment elevation in aVF, V3 - V6 e) [] Segment PR depression in aVR, V1, V2
343. CM. Tick the methods of diagnosis in acute pericarditis: a) [] EcoCG

b) [] Chest radiography c) [] Radionuclide study d) [] Stress - test e) [] Ventriculography
344. CM. Indicate the ECG characteristics of first stage acute pericarditis: a) [] Inverted T wave in aVR, V1-V2 b) [] T wave is positive in I, II, aVL c) [] ST segment elevation in aVF, V3-V6 d) [] T is negative in I, II, III, aVL e) [] T is positive in aVR, V1-V2
 345. CM. Select the laboratory tests used for the diagnosis of acute pericarditis: a) [] Serological - HIV b) [] Hepatic enzymes c) [] Lipid profile d) [] Electrolytes assessment e) [] Tuberculin testing, viral markers
 346. CM. Select the factors that determine the quantity of pericardial effusion: a) [] Patient's age b) [] Absolute volume of effusion c) [] Physiological properties of the pericardium d) [] The time of fluid accumulation e) [] Heart rate
 347. CM. Choose the criteria's of cardiac tamponade: a) [] Increased pressure in the pericardium b) [] Progressive limitation of ventricular diastolic filling c) [] Reduction of stroke volume and cardiac output d) [] Increased systolic volume e) [] Increase in stroke volume and cardiac output
348. CM. Indicate the clinical features of heart tamponade: a) [] Diaphoresis b) [] Chest pain c) [] Hypertension d) [] Tachycardia e) [] Musset sign
349. CM. Mention the methods of diagnosis in suspicion of cardiac tamponade: a) [] Chest radiography b) [] EcoCG c) [] Urography d) [] Ophthalmoscopy e) [] Pericardiocentesis
350. CM. Indicate the mechanisms of uremic pericarditis: a) [] Hyper function of parathyroid gland

 b) [] Hypercorticism c) [] Hypoglycemia d) [] Increasing of nitric catabolism metabolites e) [] Increasing of protein anabolism metabolites
351. CM. Select the neoplastic diseases leading to pericardial effusion: a) [] Lung cancer b) [] Leukemia c) [] Ovarian cyst d) [] Intestinal polyposis e) [] Leiomyosarcoma
 352. CM. Tick the heart involvement in neoplastic metastasis: a) [] Extension of mediastinal malignant mass to the pericardium b) [] Diffuse pericardial thickening and tumor infiltration c) [] Heterogeneous lipid streaks d) [] Local depigmentation e) [] Local infiltration of the pericardium
 353. CM. Tick the complications of pericarditis: a) [] Myocardial infarction b) [] Recurrent episodes of pericardial inflammation c) [] Hypertension d) [] Cardiac tamponade e) [] Constrictive pericarditis
354. CM. Indicate the laboratory investigations performed in case of acute pericarditis: a) [] Osteodensitometry b) [] Bone scintigraphy c) [] Chest radiography d) [] EcoCG e) [] ECG
355. CS. Choose the most common cause of angina pectoris: a) [] Bacterial infection b) [] Viral infection c) [] Bleeding d) [] Atherosclerosis e) [] Congenital diseases
356. CM. Select the painful forms of the heart diseases: a) [] Acute myocardial infarction b) [] Old myocardial infarction c) [] Silent angina pectoris d) [] Vasospastic angina pectoris e) [] Post infarction angina pectoris
357. CM. Choose the correct statements about progressive angina:a) [] Pain is more frequent that in previous days

 b) [] Pain is longer duration as in previous days c) [] Pain occurring in bigger effort than in previous days d) [] Pain is ameliorated at rest e) [] Pain occurs at small effort and at rest as in previous days
 358. CM. Choose correct statements for vasospastic angina: a) [] Pain is caused by stress b) [] Pain is longer than 15 minutes c) [] Pain is mandatory is caused by physical exercise d) [] Pain is caused by cold temperature e) [] Pain occurs in bigger effort than in previous days
 359. CS. Choose the correct statement about early post-infarction angina: a) [] Angina appeared after 3 weeks of acute myocardial infarction b) [] Angina occurred after 14 weeks of acute myocardial infarction c) [] Angina occurred in the 10th day after acute myocardial infarction d) [] Angina occurred in the 20th day after acute myocardial infarction e) [] Angina occurred in the 30th days after acute myocardial infarction
360. CM. Choose the correct statements about late post-infarction angina: a) [] Angina appeared the first time after 3 weeks acute myocardial infarction b) [] Angina occurred the first time after 14 weeks acute myocardial infarction c) [] Angina occurred in the 10 days after acute myocardial infarction d) [] Angina occurred in the 2 days after acute myocardial infarction e) [] Angina occurred in the 30 days after acute myocardial infarction
 361. CS. Choose the correct statement for angina "de novo": a) [] Angina appeared the first time last 3 weeks b) [] Angina occurred the first time last 14 weeks c) [] Angina occurred in the 10th days after acute myocardial infarction d) [] Angina occurred in the 20th days after acute myocardial infarction e) [] Angina occurred in the 30th days after acute myocardial infarction
 362. CM. Choose INCORRECT statements for angina "de novo": a) [] Angina appeared the first time last 3 weeks b) [] It is stable angina c) [] It is unstable angina d) [] Angina occurred after acute myocardial infarction e) [] Angina occurred in elderly
363. CM. Indicate the correct statements about ischemic heart disease: a) [] Pathological process is localized in pericardium b) [] Process is always acute c) [] Pathological process is in the coronary artery system d) [] Over 90 % are caused by atherosclerosis e) [] Blood circulation in the myocardium is increased
364. CS. Indicate EXEPTION about angina pectoris:a) [] It is transient myocardial ischemia

 b) [] It is non-reversible pathological process c) [] It is reversible pathological process d) [] It is manifested by retrosternal painful crises e) [] It is caused by disturbances of coronary circulation
 365. CM. Choose the correct statements about effort angina pectoris: a) [] Transient attacks of pain b) [] Permanent pain c) [] Pain increase by palpation of chest region d) [] Caused by imbalance between myocardial oxygen supply and demand e) [] Pain relievers at rest or during 5 min after administration of nitroglicerine
 366. CM. Indicate the characteristic of angina de novo: a) [] It is a form of stable angina b) [] It is clinical variant of myocardial infarction c) [] It is present one month from the time of the first attack d) [] Painful syndrome is more intense e) [] It is a form unstable angina
 367. CS. Indicate with what is related functional class of effort angina: a) [] Patient age b) [] Disease duration c) [] Physical activity tolerance d) [] Treatment given e) [] Smoking
368. CS. Select what defined increasing frequency, intensity and duration of angina attacks: a) [] Silent angina pectoris b) [] Unstable angina pectoris c) [] Vasospastic angina pectoris d) [] Effort angina de novo e) [] Stable effort angina
 369. CS. Indicate what form of angina is caused by coronary spasm: a) [] Effort angina b) [] De novo effort angina c) [] Vasospastic angina pectoris (Prinzmetal) d) [] Worsening angina e) [] Silent angina
370. CM. Select the modifiable risk factors for ischemic heart disease: a) [] Age b) [] Smoking c) [] Hypertension d) [] Family history e) [] Obesity
371. CM. Select the non-modifiable risk factors for ischemic heart disease: a) [] Lack of physical activity

 b) [] Smoking c) [] Age d) [] Family history e) [] Diet high in saturated fats
372. CS. Indicate which type of dyslipidemia (by Fredrickson) is associated strongly with coronary atherosclerosis: a) [] Type I b) [] Type II and III c) [] Type I d) [] Type I and IV e) [] Type III
373. CS. Choose the III functional class of stable angina according Canadian Cardiovascular Society classification: a) [] Slight limitation, with angina only during vigorous physical activity b) [] Moderate limitation, symptoms with everyday living activities c) [] Angina only during strenuous or prolonged physical activity d) [] Inability to perform any activity without angina or angina at rest, severe limitation e) [] Accesses are long- up to 30 min
 374. CM. Select the characteristics of microvascular angina: a) [] Caused by dysfunction of small coronary arteries and arterioles b) [] Caused by infection c) [] Cardiac catheterization show normal or minimal atherosclerosis of coronary arteries d) [] Caused by vascular spasm e) [] May be caused by systemic collagen vascular diseases
 375. CS. Indicate the endothelial factor with most powerful vasoconstrictor effect: a) [] Prostacycline b) [] Endotheline c) [] Angiotensine II d) [] Nitrous oxide e) [] Thromboplastic
 376. CM. Mention the factors with procoagulant action responsible in the pathogenesis of ischemic heart diseases: a) [] Tissue thromboplastin b) [] Willebrand factor c) [] Endogen heparin d) [] Platelet activating factor e) [] Collagen formation
 377. CS. Indicate the ECG sign of myocardial ischemia: a) [] QRS deflection b) [] Horizontal or down-sloping ST segment depression c) [] PQ interval shortening d) [] P wave amplitude decrease e) [] ST segment elevation

 378. CM. Choose the indication for exercise stress testing: a) [] To appreciate patient's quality of life b) [] To classify functional class of angina pectoris c) [] To confirm diagnosis of angina pectoris d) [] To diagnose the myocarditis e) [] To diagnose acute myocardial infarction
379. CS. Indicate the method for evaluation of the anatomy of the coronary artery tree: a) [] Exercise stress testing b) [] ECG at rest c) [] Coronary angiography d) [] Holter ECG monitoring e) [] Echocardiography
 380. CM. Choose what information offers echocardiography exam: a) [] Chambers diameters b) [] Determining the number of extrasystoles c) [] Pericardium state d) [] Assessment of interventricular septum thickness e) [] Cusps state
381. CS. Mention the method of investigation with determines the indications for angioplasty and aorta-coronary bypass: a) [] Holter monitoring b) [] Exercise stress testing c) [] Myocardial scintigraphy d) [] Echocardiography exam e) [] Coronary angiography
382. CM. Select groups of anti-angina drugs: a) [] diuretics b) [] nitrates c) [] Ca channel blockers d) [] statins e) [] beta blockers
 383. CS. Select the most common side effect of nitrates: a) [] Vertigo b) [] Sleepiness c) [] Abdominal pains d) [] Headache e) [] Swelling on legs
384. CM. Select the contraindications for administration of β-blockers: a) [] Sinus tachycardia b) [] Sinus bradycardia c) [] Complete AV block d) [] Hypertension

e) [] Hypotension
385. CM. Select the drugs from calcium channel blokers group: a) [] Enalapril b) [] Amlodipin c) [] Diltiazem d) [] Metoprolol e) [] Verapamil
 386. CS. Select the primary first-choice antiplatelet drug used in ischemic heart disease: a) [] Ticlopidine b) [] Dipyridamole c) [] Pentoxifylline d) [] Acetilsalicilic acide e) [] Nicotinic acid
 387. CS. Indicate from what group of drug is simvastatin: a) [] Antiplatelet b) [] Lowering cholesterol c) [] Metabolic d) [] Hypotensive e) [] Vasodilators
388. CM. Indicate the correct statements about acute myocardial infarction: a) [] It is myocardial necrosis b) [] It is a process caused by occlusion of a coronary artery c) [] It is one of the most common causes of mortality in the middle age d) [] Pathological process is reversible in 80-90 % of cases e) [] It is inflammation of myocardium
389. CS. Indicate the localization of myocardial infarction in right coronary artery occlusion: a) [] Anterior b) [] Antero- septal c) [] Inferior d) [] Extended anterior e) [] Apical
390. CS. Select the main clinical feature of acute myocardial infarction: a) [] Dizziness b) [] Retrosternal pain lasting more than 20 minutes c) [] Vomiting d) [] Fatigue e) [] Chest pain lasting 10 minutes
 391. CS. Indicate the changes of heart size detected by perrcution in acute myocardial infarction: a) [] Deviated to the right b) [] Usually normal or a little deviated to the left c) [] Always is normal d) [] Normal or a little deviated to the right

e) [] Normal or a little deviated to the left
392. CS. Indicate the correct level of blood pressure in acute myocardial infarction with cardiogenic shock: a) [] Elevated b) [] Various from case to case c) [] Obviously low d) [] Normal e) [] Obviously increased
393. CS. The formation of pathological Q waves on ECG formation in acute myocardial infarction reflects the presence of the: a) [] area of necrosis b) [] ischemic area c) [] lesion area d) [] parietal thrombus e) [] left ventricle aneurysm
394. CS. Mention the process that ST segment elevation shows in acute myocardial infarction a) [] Area of necrosis b) [] Ischemic area c) [] Damage area d) [] Parietal thrombus e) [] Cardiogenic shock
 395. CM. Indicate the correct statements about initial phase of acute myocardial infarction: a) [] Lasts several hours b) [] Lasts several weeks c) [] Elevation of ST segment d) [] Izoelectrical ST segment e) [] Presence of pathological Q wave
396. CM. Select the earliest recognized signs of ST elevation acute myocardial infarction on ECG: a) [] Peaked T waves b) [] ST segment depression c) [] ST segment elevation d) [] ST segment returns to isoline e) [] T wave stabilization
397. CS. Choose the leads of direct ECG signs in anteroseptal myocardial infarction: a) [] V3 -V4 b) [] V1-V3 c) [] V1-V4 d) [] II, III, AVF e) [] V 5-V6, I, AVL
398. CS. Choose the leads of direct ECG signs in inferior myocardial infarction: a) [] V3 -V4

c) d)) [] V1-V2) [] V1-V4) [] II, III, AVF) [] V5-V6, I, AVL
D a) b) c) d) m	899. CM. Select criteria of definition in acute myocardial infarction according Third Universal efinition: [] Detection of rise of biomarker values with symptoms of ischemia [] Detection of rise of biomarker values with new significant ST-T changes or new LBBB [] Detection of rise of biomarker values with PQ changes [] Detection of rise of biomarker values with imaging evidence of new loss of viable syocardium [] Detection of rise of biomarker values with syncope
a) b) c) d)	100. CM. Select the ECG signs for acute myocardial infarction: [] T wave inversion [] Development of Q waves in the ECG [] Appearance of complete SA block [] Depression of ST segment [] Elevation of ST segment lasting more than 24 hours
a) b) c) d)	101. CS. Indicate the laboratory changes included in diagnosis of acute myocardial infarction: [] C-reactive protein increase [] Dyslipidemia [] Rise cardiac biomarkers [] Increased ESR [] Leucocytoses
ui a) b) c) d)	102. CS. Indiçâtes the criteria of differential diagnosis of acute myocardial infarction and instable angina pectoris: [] Character of pain [] Time of angina syndrome [] Increasing of cardiac troponin [] Effect of nitroglycerin administration [] Blood pressure
in a) b) c) d)	103. CM. Indicate the criteria to différentiâtes of acute péricardites witz the acute myocardique fraction: [] Increasing of pain to deep breathing [] Appearance of pathological Q wave [] Increasing of cardiac troponin [] ST segment elevation is consistent in all derivations [] ST segment elevation sound be found in two contiguous leads
a) b) c)	104. CM. Choose the mechanical complications of acute myocardial infarction: [] Dressler syndrome [] Rupture of the heart wall [] Left ventricle aneurysm [] Cardiogenic shock

e) [] Ventricular arrhythmias
405. CS. Indicate the localization of acute myocardial infarction complicated more frequently by AV block: a) [] Inferior b) [] Anterior c) [] Lateral d) [] Septal e) [] Anteroseptal
406. CS. Mention what is involved in post infarction Dressler syndrome: a) [] Myocardium b) [] Pericardium c) [] Endocardium d) [] Mediastinum e) [] Vessels
407. CM. Indicate the first emergency measures recommended in acute myocardial infarction: a) [] Sublingual nitroglycerin b) [] Aspirin 250-500 mg c) [] Antibiotics d) [] Amiodaron e) [] Oxygen
 408. CM. Select what is included in reperfusion treatment of acute myocardial infarction: a) [] Thrombolytic drugs b) [] Antiplatelet c) [] Anticoagulants d) [] Coronary angioplasty e) [] ACE inhibitors
409. CS. Indicate the dose of intravenous bolus of unfractionated heparin recommended in acute myocardial infarction: a) [] 12 U/kg b) [] 60 U/kg c) [] 100 U/kg d) [] 25 U/kg e) [] Decision of the physician
410. CM. Select the drug from thrombolytic group recommended in acute myocardial infarction: a) [] Heparin b) [] Streptokinase c) [] Alteplase d) [] Aspirin e) [] Reteplase
411. CM. Indicate what included secondary prevention of acut myocardial infarction: a) [] Statins b) [] Antiplatelet therapy

c) [] β-blockers d) [] Anticoagulants e) [] Diuretics
412. CS. Indicate what represents systemic blood pressure: a) [] The product between cardiac output and peripheral resistance b) [] The product between heart rate and preload c) [] Is the product between intrinsic myocardial contractility and preload d) [] The product between heart rhythm and preload e) [] The product between heart valve competence and post load
413. CM. Indicate the determinants of cardiac output: a) [] Intrinsic myocardial contractility b) [] Frequency and heart rate c) [] Preload d) [] Activity of the autonomic nervous system e) [] Activity of the central nervous system
 414. CM. Select what determine vascular resistance: a) [] Blood viscosity b) [] The length of the arterial segment c) [] Hyper insulinemia d) [] Renal retention of water and salt e) [] Vascular lumen
415. CS. Indicate the sign of hypertensive vascular remodeling: a) [] Vasoconstriction b) [] Increased arterial stiffness c) [] Increasing the mean thickness relative to the diameter of the vascular lumen d) [] Reengaged smooth muscle cells e) [] Vascular smooth muscle hypertrophy
416. CS. Indicate the value of intima-media index as subclinical target organs involvment in hypertension: a) [] > 0.5 mm b) [] > 0.6 mm c) [] > 0.7 mm d) [] > 0.8 mm e) [] > 0.9 mm
417. CM. Indicate the values of ankle-arm index as subclinical damage of vassels in hypertension: a) [] > 1.3 b) [] < 0.12 c) [] < 0.11 d) [] < 0.10 e) [] < 0.9

418. CM. Select the criteria for subclinical kidney damage in hypertension:

 a) [] Decreasing of glomerular filtration rate <60 ml/min/1.73 m2 b) [] Decreasing of creatinine clearance <60 ml/min c) [] Decreasing of glomerular filtration rate > 80 ml/min/1.73 m2 d) [] Decreasing of creatinine clearance > 80 ml / min e) [] Micro albuminuria 30 - 300 mg/24h
419. CS. Indicate the velocity of the carotid-femoral pulse in subclinical organ damage in hypertension: a) [] > 8 m/s b) [] > 9 m/s c) [] > 10 m/s d) [] > 11 m/s e) [] > 12 m/s
420. CS. Choose the diet recommended in hypertension: a) [] Potassium-rich food b) [] Magnesium-rich food c) [] Calcium-rich food d) [] Iron-rich food e) [] Sodium-rich food
 421. CS. Indicate NOT recommended combination of drugs in patients with metabolic syndrome: a) [] Beta blocker and thiazide diuretics b) [] Calcium channel blocker and conversion enzyme inhibitors c) [] Calcium channel blocker and angiotensin receptor antagonist d) [] Calcium channel blocker and thiazide diuretic e) [] Beta blocker and calcium channel blocker
422. CM. Select the drugs recommended in isolated systolic hypertension in the elderly: a) [] Diuretics b) [] Calcium channel blockers c) [] Alpha-1 blockers d) [] Alpha-2 agonists with central action e) [] Direct vasodilators
423. CS. Indicate the groups of drugs delay the occurrence of nephropathy in hypertension with diabetes: a) [] Beta blockers b) [] Thiazide diuretics c) [] Diuretics that save potassium d) [] Aldosterone Receptor Antagonists e) [] Conversion enzyme inhibitors
424. CM. Indicate the drugs recommended in high blood pressure in pregnancy: a) [] Metildopa b) [] Conversion enzyme inhibitors c) [] Sartans d) [] Amiodarone

e) [] Calcium channel blockers
425. CS. Indicate the elective drug used in hypertension with aortic dissection: a) [] Captopril b) [] Enalapril c) [] Lisinopril d) [] Ramipril e) [] Nitroprusside of sodium
 426. CM. Indicate the mechanism of increasing blood pressure by angiotensin II: a) [] Stimulation of γ-aminobutyric acid b) [] Stimulation of aldosterone secretion c) [] Increasing central sympathetic tone d) [] Facilitating the release of noradrenaline e) [] Vasoconstriction
427. CS. Indicate the antiplatelet dose of acetylsalicylic acid: a) [] 25-50 mg/day b) [] 50-65 mg/day c) [] 75-100 mg/day d) [] 110-150 mg/day e) [] 325 mg/day
428. CS. Indicate the antiplatelet mechanism of acetylsalicylic acid: a) [] Inhibiting of hepatic cytochrome oxidases b) [] Inhibiting of serotoninergic action c) [] Inhibiting of H1 receptors d) [] Inhibiting of H2 receptors e) [] Inhibiting synthesis of thromboxane A2
429. CS. Mention the clinical characteristic of the I stage of hypertension: a) [] Ventricular hypertrophy b) [] Generalized or local narrowing of the retinal artery c) [] Proteinuria and/or mild increases in serum creatinine d) [] Lack of signs of damage of the target organs e) [] Atherosclerotic plaques demonstrated angiographically
 430. CS. Indicate the cause of "Salus-Gunn"/cross sign in hypertension: a) [] Linear or oval bleeding in the retina b) [] Retinal edema c) [] Diffuse edema of the optic nerve papilla d) [] Local spasm or generalized narrowing of the retinal arteries e) [] Local compression of the veins by the twisted arteries in the place of their crossing
 431. CS. Indicate what show the cross sign or "Salus-Gunn" in hypertensive patients: a) [] Short-term hypertension b) [] Long-term hypertension c) [] Macular hemorrhage d) [] Marked papillary edema

e) [] Foggy view
432. CM. Mention the clinical characteristics of the II stage of hypertension: a) [] Left ventricular hypertrophy b) [] Generalized or local narrowing of the retinal artery c) [] Stroke d) [] Moderate proteinuria and/or mild increases in plasma creatinine e) [] Atherosclerotic plaques demonstrated angiographically or ultrasonographically
 433. CS. Indicate what reflects the "gallop rhythm" by auscultation in hypertensive patients: a) [] Atherosclerotic lesions of mesenteric arteries b) [] Affected ventricular compliance c) [] Arterial lesions that occur in systemic vasculitis d) [] Malignant hypertension e) [] Reflects kidney damage
434. CS. Indicate the value of isolated systolic hypertension: a) [] Systolic blood pressure 130 - 139, diastolic 85 - 89 mmHg b) [] Systolic blood pressure ≥180, diastolic ≥110 mmHg c) [] Systolic blood pressure≥140, diastolic <90 mmHg d) [] Systolic blood pressure 160 - 179, diastolic 100 - 109 mmHg e) [] Systolic blood pressure 140 - 159, diastolic 90 - 99 mmHg
 435. CS. Mention what indicate the marked jugular turgescence in patients with hypertension: a) [] Aortic Coarctation b) [] Truncular obesity c) [] Biventricular serious decompensation d) [] Cushing's syndrome e) [] Superficial thrombophlebitis
 436. CM. Choose the typical symptoms in hypertension: a) [] Headache b) [] Diarrhea c) [] Neuropsychic manifestations (irritability, anxiety, asthenia) d) [] Visual and auditory disorders (blurred vision, scotomas, tinnitus) e) [] Constipation
437. CS. Mention what signals the pulse asymmetry at the upper limbs in hypertension: a) [] Hypertensive crisis b) [] Aortic dissection c) [] Obesity d) [] Asthenic personality e) [] Cerebrovascular damage
 438. CS. Indicate the II degree (moderate) of hypertension: a) [] Systolic blood pressure ≥ 140, diastolic <90 mmHg b) [] Systolic blood pressure 160-179, diastolic 100 - 109 mmHg c) [] Systolic blood pressure 130-199, diastolic 85 - 89 mmHg d) [] Systolic blood pressure 140-159, diastolic 90 - 99 mmHg

e) [] Systolic blood pressure \geq 180, diastolic \geq 110 mmHg
 439. CS. Indicate the III degree (severe) hypertension: a) [] Systolic blood pressure ≥140, diastolic <90 mmHg b) [] Systolic blood pressure 160-179, diastolic 100-109 mmHg c) [] Systolic blood pressure 130-199, diastolic 85-89 mmHg d) [] Systolic blood pressure 140-159, diastolic 90-99 mmHg e) [] Systolic blood pressure ≥ 180, diastolic ≥110 mmHg
 440. CM. Indicate the X-ray signs of venous pulmonary congestion in hypertension: a) [] Emphasis of the lung drawing on the account of the vascular component b) [] "Image of 3" c) [] Interstitial lung edema d) [] Alveolar pulmonary edema e) [] Coastal erosion
 441. CM. Indicate the X-ray signs of aortic coarctation: a) [] "Image of 3" b) [] Emphasis of the lung drawing on the account of the vascular component c) [] Interstitial lung edema d) [] Alveolar pulmonary edema e) [] Coastal erosion
442. CM. Mention what included the brain damages in III stage of hypertension: a) [] Transient ischemic attack b) [] The stroke c) [] Advanced hypertensive encephalopathy d) [] Generalized or local narrowing of the retinal artery e) [] Intermittent claudication
443. CS. Indicate what suggest diastolic murmur by auscultation at aortic point in hypertensions a) [] Aortic stenosis b) [] Aortic dissection with proximal extension to the aortic valve c) [] Impaired cardiac compliance d) [] Increase of telediastolic pressure in LV e) [] The presence of noise III and IV in heart auscultation
444. CM. Choose the characteristics for hypertension in Cushing's syndrome: a) [] Truncal obesity (androgen redistribution of adipose tissue) b) [] "Full moon face" c) [] Skin atrophy with manifest vascular drawing d) [] Rosacea in the lower abdomen e) [] "Livedo reticularis"
 445. CS. Indicate the ECG sign of the Socolov - Lyon Index in hypertension: a) [] Increased R wave voltage in all thoracic branches b) [] S (V1) + R (V5 or V6) ≥ 35 mm c) [] The T wave is flattened or negative d) [] Depressed ST segment

e) [] Deviation of the heart shaft (AEC) to the left
446. CS. Indicate the I degree (mild) hypertension: a) [] Systolic blood pressure ≥ 140 mmHg, diastolic blood pressure <90 mmHg b) [] Systolic blood pressure 160 - 179 mmHg, diastolic blood pressure 100 - 109 mmHg c) [] Systolic blood pressure 130 - 199 mmHg, diastolic blood pressure 85 - 89 mmHg d) [] Systolic blood pressure 140 - 159 mmHg, diastolic blood pressure 90 - 99 mmHg e) [] Systolic blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 110 mmHg
447. CM. Choose the criteria used to assess cardiovascular risk in patients with hypertension: a) [] Total cholesterol b) [] HDL-cholesterol c) [] C-reactive protein d) [] Abdominal obesity e) [] Smoking
 448. CM. Indicate the clinical features of hypertensive cardiomyopathy: a) [] Palpitations b) [] Fever c) [] Syncope d) [] Dyspnea on exertion e) [] Deafness
449. CM. Mention the ECG characteristics of monomorphic extrasystoles: a) [] Coupling intervals are different b) [] Extrasystoles, in the same deviation, have different shapes c) [] Extrasystoles are from the same outbreak d) [] Coupling intervals are equal e) [] Extrasystoles are from different outbreaks
 450. CS. Indicate the ECG sign of ventricular extrasystoles: a) [] Norrow QRS complex b) [] Incomplete compensatory pause c) [] PQ interval less than 0,12 sec d) [] Negative P wave after QRS complex e) [] Absence of P wave
 451. CS. Indicate the ECG sign of the upper atrioventricular extrasystoles: a) [] P-Q interval more than 0,20 sec b) [] Abnormal QRS complex c) [] Negative P wave in II, III before QRS complex d) [] Negative P wave in DII, DIII after QRS complex e) [] Full compensatory pause
 452. CS. Indicate the ECG sign of the middle atrioventricular extrasystole: a) [] Abnormal QRS complex b) [] Negative P wave in II, III after QRS complex c) [] P waves embedded in QRS complex d) [] Full compensatory pause

e) [] Negative P wave in II, III before QRS complex
453. CS. Indicate the ECG sign of lower atrioventricular extrasystoles: a) [] Absence of P wave b) [] Abnormal QRS complex c) [] Full compensatory pause d) [] Negative P wave after QRS complexul e) [] PQ interval more than 0,2 sec
 454. CM. Select the type of extrasystoles according periodicity: a) [] Bigeminy b) [] Trigeminiy c) [] Quadrigeminy d) [] Monomorphic e) [] Polymorphic
 455. CS. Indicate the mechanism of action of Class I antiarrhythmic drugs: a) [] Potassium channel blockers b) [] Sodium channel blockers c) [] Calcium channel blockers d) [] β-blockers e) [] Potassium channel blockers
456. CS. Note the mechanism of action of Class II antiarrhythmic drugs: a) [] Potassium channel blockers b) [] Sodium channel blockers c) [] Calcium channel blockers d) []β-blockers e) [] Potassium channel blockers
457. CM. Note the mechanisms of action of Class III antiarrhythmic drugs: a) [] Potassium channel blockers b) [] Sodium channel blockers c) [] Calcium channel blockers d) []β-blockers e) [] Potassium channel blockers
458. CS. Tick the mechanism of action of class IV antiarrhythmic drugs. a) [] Potassium channel blockers b) [] Sodium channel blockers c) [] Calcium channel blockers d) []β-blockers e) [] Potassium channel blockers
459. CS. Tick the antiarrhythmic drug that acts on the "if" channel: a) [] Amiodarone b) [] Sotalol c) [] Ivabradine d) [] Metoprolol

460. CM. Mention the drugs for rate control in patients with chronic atrial fibrillation: a) [1 Amiodarone b) [1 Digoxin c) [1 Bisoprolod d) [1 Warfarin e) [1 Amlodipine 461. CM. Mention the drugs for rhythm control in patients with atrial fibrillation: a) [1 Amiodarone b) [1 Digoxin c) [1 Bisoprolod d) [1 Warfarin e) [1 Amlodipine 462. CS. Choose the method of choice of treatment in patients with recidivant ventricular tachycardia: a) [1 Pacemaker implantation b) [1 Transesophageal stimulation e) [1 Ablation d) [1 Cardiodefibrillator implantation e) [1 Heart transplantation 463. CS. Mention the score used to assess thromboembolic risk in patients with atrial fibrillation a) [1 EHRA b) [1 SCORE e) [1 VAS d) [1 CHA2DS2-VASC e) [1 Framingham 464. CM. Note the criteria included in the CHA2DS2 score used in patients with atrial fibrillation: a) [1 Hypertension b) [1 Heart failure e) [1 Stroke d) [1 Age more than 65 years e) [2 Peripheral arterial disease 465. CM. Note the criteria included in the CHA2DS2VASC score used in patients with atrial fibrillation: a) [1 Diabetes mellitus b) [1 Heart failure e) [1 Stroke d) [1 Age more than 75 years e) [1 Viral hepatitis	e) [] Nicorandil
a) [] Amiodarone b) [] Digoxin c) [] Bisoprolol d) [] Warfarin e) [] Amlodipine 462. CS. Choose the method of choice of treatment in patients with recidivant ventricular tachycardia: a) [] Pacemaker implantation b) [] Transesophageal stimulation c) [] Ablation d) [] Cardiodefibrillator implantation e) [] Heart transplantation 463. CS. Mention the score used to assess thromboembolic risk in patients with atrial fibrillation a) [] EHRA b) [] SCORE c) [] WAS d) [] CHA2DS2-VASC e) [] Framingham 464. CM. Note the criteria included in the CHA2DS2 score used in patients with atrial fibrillation: a) [] Hypertension b) [] Heart failure c) [] Stroke d) [] Age more than 65 years e) [] Peripheral arterial disease 465. CM. Note the criteria included in the CHA2DS2VASC score used in patients with atrial fibrillation: a) [] Diabetes mellitus b) [] Heart failure c) [] Stroke d) [] Age more than 75 years e) [] Viral hepatitis	 a) [] Amiodarone b) [] Digoxin c) [] Bisoprolol d) [] Warfarin
tachycardia: a) [] Pacemaker implantation b) [] Transesophageal stimulation c) [] Ablation d) [] Cardiodefibrillator implantation e) [] Heart transplantation 463. CS. Mention the score used to assess thromboembolic risk in patients with atrial fibrillation a) [] EHRA b) [] SCORE c) [] VAS d) [] CHA2DS2-VASC e) [] Framingham 464. CM. Note the criteria included in the CHA2DS2 score used in patients with atrial fibrillation: a) [] Hypertension b) [] Heart failure c) [] Stroke d) [] Age more than 65 years e) [] Peripheral arterial disease 465. CM. Note the criteria included in the CHA2DS2VASC score used in patients with atrial fibrillation: a) [] Diabetes mellitus b) [] Heart failure c) [] Stroke d) [] Age more than 75 years e) [] Viral hepatitis	 a) [] Amiodarone b) [] Digoxin c) [] Bisoprolol d) [] Warfarin
a) [] EHRA b) [] SCORE c) [] VAS d) [] CHA2DS2-VASC e) [] Framingham 464. CM. Note the criteria included in the CHA2DS2 score used in patients with atrial fibrillation: a) [] Hypertension b) [] Heart failure c) [] Stroke d) [] Age more than 65 years e) [] Peripheral arterial disease 465. CM. Note the criteria included in the CHA2DS2VASC score used in patients with atrial fibrillation: a) [] Diabetes mellitus b) [] Heart failure c) [] Stroke d) [] Age more than 75 years e) [] Viral hepatitis	tachycardia: a) [] Pacemaker implantation b) [] Transesophageal stimulation c) [] Ablation d) [] Cardiodefibrillator implantation
464. CM. Note the criteria included in the CHA2DS2 score used in patients with atrial fibrillation: a) [] Hypertension b) [] Heart failure c) [] Stroke d) [] Age more than 65 years e) [] Peripheral arterial disease 465. CM. Note the criteria included in the CHA2DS2VASC score used in patients with atrial fibrillation: a) [] Diabetes mellitus b) [] Heart failure c) [] Stroke d) [] Age more than 75 years e) [] Viral hepatitis	a) [] EHRA b) [] SCORE c) [] VAS d) [] CHA2DS2-VASC
fibrillation: a) [] Diabetes mellitus b) [] Heart failure c) [] Stroke d) [] Age more than 75 years e) [] Viral hepatitis	 464. CM. Note the criteria included in the CHA2DS2 score used in patients with atrial fibrillation: a) [] Hypertension b) [] Heart failure c) [] Stroke d) [] Age more than 65 years

466. CM. Indicate difference between CHA2DS2-VASC and CHADS2 score used in atrial fibrillation:

 a) [] Myocardial infarction b) [] Heart failure c) [] Stroke d) [] Age e) [] Peripheral arterial disease
 467. CS. Indicate the correct statement for type bigeminy of extrasistoles a) [] Each of the 2-nd beat is an extrasystoles b) [] Each of the 3-nd beat is an extrasystoles c) [] Each of the 4-th beat is a extrasystoles d) [] Doublets e) [] Triplets
 468. CS. Choose the correct statement for estrasystolc alloritmia type trigeminy: a) [] Each of the 2-nd beat is an extrasystoles b) [] Each of the 3-nd beat is an extrasystoles c) [] Each of the 4-th beat is a extrasystoles d) [] Doublets e) [] Triplets
 469. CS. Choose the correct statement for extrasystolic arrhythmia type quadrigeminy: a) [] Each of the 2-nd beat is an extrasystoles b) [] Each of the 3-nd beat is an extrasystoles c) [] Each of the 4-th beat is a extrasystoles d) [] Doublets e) [] Triplets
470. CS. Choose the correct statement of three succeeded extrasystoles on ECG: a) [] Ventricular extrasystoles b) [] Supraventricular extrasystoles c) [] Trigimeny d) [] Doublet e) [] Triplet
471. CS. Choose the correct statement of two succeeded extrasystoles on ECG: a) [] Ventricular extrasystoles b) [] Supraventricular extrasystoles c) [] Trigimeny d) [] Doublet e) [] Triplet
472. CS. Choose the correct statement for the extrasystolic triplets on ECG: a) [] Each of the 2-nd beat is an extrasystoles b) [] Each of the 3-nd beat is an extrasystoles c) [] Each of the 4-th beat is a extrasystoles d) [] Presence of two succeeded extrasystoles e) [] Presence of three succeeded extrasystoles

473. CM. Select the chronic forms of ischemic heart disease:

 a) [] Sudden death b) [] Stable angina pectoris c) [] Silent angina pectoris d) [] Acute myocardial infarction e) [] Unstable angina
474. CM. Select the acute forms of ischemic heart disease: a) [] Sudden cardiac death b) [] Stable angina pectoris c) [] Silent angina pectoris d) [] Acute myocardial infarction e) [] Unstable angina
 475. CM. Select no atherosclerotic causes of ischemic heart disease: a) [] Vasculitis b) [] Acute viral infection c) [] Tuberculosis d) [] Myocardial bridges e) [] Aortic dissection
 476. CS. Select the correct name of small coronary arteries and arterioles involvement: a) [] Unstable angina b) [] Old myocardial infarction c) [] Silent angina pectoris d) [] Vasospastic angina pectoris e) [] Microvascular angina
477. CS. Indicate the myocardial functions which are impairment in angina pectoris: a) [] Metabolic, mechanical and electrical b) [] Metabolic only c) [] Mechanical and electrical d) [] Metabolic and mechanical e) [] Electrical only
478. CM. Select the invasive methods of revascularization for patients with ischemic heart diseases: a) [] Percutaneous intervention procedures b) [] Valve replacement c) [] Coronary artery bypass graft d) [] Myomectomy e) [] Ablation
479. CM. Indicate the correct statements for unstable angina: a) [] New onset of ischemic symptoms b) [] Recurrence of ischemic symptoms within 4-6 month after an acute myocardial infarction c) [] Intensification of previous ischemic symptoms d) [] Change in pattern (egg, symptoms at rest) e) [] Ischemic symptoms on physical exercise for 3 month

 480. CM. Indicate the ECG abnormalities in patients with unstable angina: a) [] Transient ST-segment depression or elevation b) [] PQ prolongation c) [] T wave inversion d) [] Irregular RR interval e) [] Absents of QRS complexes
481. CM. Indicate the correct statements for unstable angina pectoris: a) [] Ischemic symptoms are developing in rest with duration more than 10 minutes b) [] The age of patient over 60 years c) [] Intensification of previous angina pain d) [] Myocardial infarction in anamnesis e) [] Increasing of the frequency of angina pain attacks
482. CS. Choose the method of diagnosis in ST elevation acute myocardial infarction: a) [] Stress - test echocardiography b) [] Assessment of cardiac biomarkers c) [] Stress-test ECG d) [] Holter monitoring ECG e) [] Pulmonary X ray
483. CM. Indicate the characteristics for chronic heart failure stage B (ACC/AHA classification) a) [] Absents of structural cardiac changes b) [] Presence of structural cardiac changes c) [] Absence of symptoms and signs of heart failure d) [] Presence of symptoms and signs of heart failure e) [] Presence of symptoms in rest
484. CM. Choose the causes of pressure overload of heart failure: a) [] Hypertension b) [] Aortic stenosis c) [] Valvular regurgitations d) [] Myocardial ischemia e) [] Primary cardiomyopaties
485. CM. Choose the causes of volume overload of heart failure: a) [] HTA b) [] Intracardiac shunts c) [] Arteriovenous fistulas d) [] Valvular regurgitations e) [] Valvular stenosis
486. CM. Choose the causes with contractility involvement in heart failure: a) [] Myocarditis b) [] Endocrine diseases c) [] Valvular stenosis d) [] Myocardial ischemia e) [] Intracardiac shunts

 487. CM. Choose the mechanism of cardiac adaption in heart failure: a) [] Frank-Starling mechanism b) [] Sympathetic nervous system activation c) [] Parasympathetic nervous system activation d) [] Reentry mechanism e) [] Renin-angiotensin system activation
488. CM. Mention the signs of left sided chronic heart failure: a) [] Peripheral edema b) [] Subicteric skin c) [] Hepatomegaly d) [] Tachicardia e) [] Sistolic murmur on the apex
 489. CM. Mention the signs of right sided chronic heart failure: a) [] Cianosis b) [] Jugular turgescence c) [] Moist pulmonary crackles d) [] Peripheral edema e) [] Hepatomegaly
490. CM. Mention the simptoms of right sided chronic heart failure: a) [] Dispneea b) [] Cough c) [] Hemoptysis d) [] Hepatalgia e) [] Peripheral edema
491. CM. Mention the simptoms of left sided chronic heart failure: a) [] Dispneea b) [] Cough c) [] Hepatalgia d) [] Bloating e) [] Peripheral edema
492. CM. Mention the laboratory signs of chronic heart failure: a) [] Anemia b) [] Hyponatremie c) [] Hypernatriemie d) [] Hematocrit increasing e) [] Proteinuria
493. CM. Choose factors of poor prognostic in heart failure: a) [] Male b) [] Female c) [] Ischemic heart disease d) [] Hypotension e) [] Cachexia

 494. CS. Indicate the treatment target in cardiogenic shock: a) [] Cardiac output normalization b) [] Normalization of volemia c) [] Dicreasing of blood presure d) [] Antiagregation e) [] Normalization of presure in pulmonary artery
 495. CM. Choose the criteria for diagnosis of isolated right heart failure: a) [] Hypotension b) [] Low cardiac output c) [] Normal cardiac output d) [] Normal blood presure e) [] Hight cardiac output
 496. CS. Indicate the treatment target in isolated right heart failure: a) [] Normalization of presure in pulmonary artery b) [] Normalization of volemia c) [] Increasing of blood presure d) [] Antiagregation e) [] Normalization of cardiac output
497. CM. Indicate the inotropic medications recommended for acute heart failure: a) [] Bisoprorol b) [] Dopamine c) [] Levosimendan d) [] Milrenon e) [] Neseritide
498. CM. Mention the symptoms caused by hypoperfusion in acute heart failure: a) [] Fatigue b) [] Confusion c) [] Cough d) [] Syncope e) [] Peripheral edema
499. CM. Mention the symptoms related by the congestion in acute heart failure: a) [] Moist pulmonary crackles b) [] Polyuria c) [] Tahicardia d) [] Peripheral edema e) [] Syncope
500. CM. Choose the causes of cardiogenic shock in acute myocardial infarction: a) [] Rupture of the papillary muscle b) [] Ventricular tachycardia c) [] Severe bradycardia d) [] Acute hemorrhage after fibrinolysis e) [] Supradosage of diuretics

- 501. CS Choose the ECG sign specific for CRBBB
- a. Presence of large R waves in III, aVF, V1, V2
- b. Elongation of PQ interval
- c. Shortening of PQ interval
- d. Presence of large R waves in I, aVL, V5, V6
- e. Presence of large S waves in III, aVF, V1, V2
- **502**. CS Choose the direct indication for cardio stimulator implantation
- a. multiple paroxysms of ventricular fibrillation in variable periods of time
- b. complete AV block
- c. atrial fibrillation
- d. atrial flutter
- e. left bundle branch block
- **50**3. CM Choose what is specific for complete AV block
- a. frequently is congenital
- b. syncope is a characteristic complaint
- c. in case of physical effort and stress, the HR rises up to 100 c/min
- d. the escape rhythm frequency do not exceed 40 c/min
- e. almost every time is acquired
- **50**4. CM What is the ECG pattern for II nd degree sino-atrial block
- a. periods sinusal pause without P waves
- b. periodic absence of PQRS complex
- c. compensatory complete pauses after PQRST
- d. atrial and ventricular frequent contractions
- e. PQ elongation
- 505. CM Specific ECG patterns for anterior complete left bundle branch block
- a. type R complexes in I, aVL, V5, V6
- b. EAH extremely left deviated
- c. type S complexes in III, aVF, V1, V2
- d. QRS duration 0.1 0.12 seconds

- e. junctional rhythm
- **50**6. CM Choose the rhythm disturbances that do not induce severe hemodynamics changes
- a. 3rd degree AV block
- b. 3rd degree SA block
- c. 1st degree AV block
- d. 1st degree SA block
- e. sinusal bradycardia
- **50**7. CS. Name the causal mechanism of atrioventricular junction tachycardia:
- a. impulse conduction disorder through the re-entry mechanism
- b. automatic disorder through the trigger mechanism
- c. increase in normal automatism
- d. insufficiency of normal automatism
- e. the parasystolic mechanism
- **50**8. CM. Choose medications that is NOT included in the treatment of patients with obstructive hypertrophic cardiomyopathy:
- a. cardiac glycosides
- b. beta blocker
- c. nitrates
- d. diuretics
- e. antiarrhythmic
- 509. CM List the surgical methods used in the treatment of patients with significant obstructive hypertrophic cardiomyopathy:
- a. partial myectomy
- b. septal ablation with alcohol
- c. embolization of the first septal
- d. implantation of the defibrillator cardioverter
- e. total myoectomy
- 510. CM Mention the pathologies that can develop a restrictive cardiomyopathy:
- a. eosinophilic endomyocardial fibrosis (Loffler syndrome)
- b. cardiac amyloidosis

- c. systemic lupus erythematosus
- d. hemochromatosis
- e. irradiated heart damage
- 511. CM. Select the risk factors for sudden cardiac death:
- a. heredity
- b. hypercathecolamines
- c. alcohol consumption
- d. obesity
- e) social status
- 512. CM List which of the major factors of sudden cardiac death are:
- a. fever < 40%
- b. low vital capacity
- c. complex ventricular rhythm disorders
- d. abnormalities in the neuro-hormonal control of cardiac function
- e. psychosocial factors
- 513. CM List which of the following conditions can cause sudden cardiac death by non-arrhythmic mechanisms:
- a. electromechanical dissociation
- b. cardiac tamponade
- c. aortic dissection
- d. ventricular tachycardia
- e. asystole
- 514. CM The following concepts are true about assessing the risk of sudden death:
- a. is performed in 4 stages
- b. in 1 stage the characterization of the causal disease and the associated favoring factors is made.
- c. in the 2nd stage the risk stratification is performed, using invasive and / or non-invasive methods
- d. in the last stage the criteria and markers are established on the basis of which the effectiveness of the treatment will be assessed
- e. is performed in 5 stages
- 515. CM Select to stratify the risk of sudden death will be assessed:

- a. left ventricular function
- b. the presence and severity of myocardial ischemia
- c. function of both ventricles
- d. the mechanism of ventricular arrhythmias
- e. disorders of neuro-hormonal regulation of cardiac function
- 516. CM Write down the stress tests in sudden cardiac death:
- a. are invasive tests
- b. useful for stratifying the prognosis of patients
- c. evaluates the functional capacity
- d. identify ventricular arrhythmia
- e. are useful for guiding the therapeutic attitude
- 517. CM Select to prevent life-threatening arrhythmias and sudden deaths:
- a. is simple
- b. drug therapy may be used
- c. surgical means may be used
- d. defibrillators can be implanted
- e. aims to reduce the risk of sudden death
- 518. CM Note the prophylaxis of sudden death by drug treatment, administered chronically is done with:
- ß blocker
- b. quinidine
- c. amiodarone
- d. flecainide
- e. propafenone
- 519. CM Select which surgical methods used to prevent sudden cardiac death are:
- a. excision of the left stellate ganglion in patients with sdr. QT prolonged
- b. subendocardial ventriculotomy
- c) aneurysmectomy
- d. aortocoronarian by pass
- e. aortofemoral by pass

- 520. CM Mention the purpose of cardiovascular recovery:
- a. reducing the risk of sudden death
- b. reduction of infarction
- c. control of cardiac symptoms
- d. waist control
- e. regression of atherosclerosis
- 521. CM. Note the clinical signs of suspicion of a non-syncope fall:
- a. the presence of post-critical disorientation
- b. tonic-clonic seizures, which begin with access
- c. frequent seizures with multiple somatic charges, without organic damage to the heart
- d. the association of the fall with vertigo
- e. association of fall with dysarthria, diplopia
- 522. CM Select which factors increase the chance of a rhythm disorder causing syncope?
- a. heart rate too low
- b. heart rate too fast
- c. left ventricular function with normal ejection fraction
- d. left ventricular function with low ejection fraction
- e. ventricular arrhythmia
- 523. CM To evaluate neurogenic-mediated syncope, the following is performed:
- a. carotid sinus massage
- b. tilt test
- c. long-term ECG monitoring (Holter, implantable devices)
- d. electrophysiological study
- e. echocardiography
- 524. CM Select which of the following statements is correct for Tilt the test:
- a. is indicated in the diagnosis of syncope of unidentified genesis
- b. is especially indicated in patients with intact heart
- c. the positive test (loss of consciousness with induction of hypotension and / or bradycardia) is considered a diagnosis for vaso-vagal syncope
- d. positive test (loss of consciousness with induction of hypertension)

- e. positive test (loss of consciousness with induction of tachycardia)
- 525. CM Choose the characteristics of the EKG in manifest mitral regurgitation:
- a. hypertrophy LA
- b. the horizontal axis of the cord or a deviation to the left
- c. hypertrophie LV
- d. atrial fibrillation
- e. RA hypertrophy
- 526. CM Choose auscultative changes in the heart in mitral stenosis:
- a. clicking noise I at the apex
- b. diminished noise I at the apex
- c. systolic murmur at the apex
- d. diastolic murmur at the apex
- e. mitral valve opening noise
- 527. CM Choose the correct statements for severe mitral stenosis:
- a. area of the mitral orifice> 1.5 cm2
- b. area of mitral orifice <1 cm2
- c. the area of the mitral orifice is 1.4 cm²
- d. the average pressure in LA is> 30 mmHg
- e. the average pressure in the LA is 20 mmHg
- 528. CM Select which pathological conditions can produce a clinical appearance of mitral stenosis:
- a. atrial myxoma
- b. pedicle atrial thrombus
- c. vegetation
- d. right branch block of the Hiss fascicle
- e. left branch block of the Hiss fascicle
- 529. CM Note the consequences when the area of the mitral orifice falls below 2 cm2:
- a. the pressure in the LA decreases
- b. the pressure in the LA increases
- c. dyspnea of varying degrees occurs up to acute pulmonary edema
- d. the pressure in the LA is transmitted into the pulmonary veins

- e. the pressure in the atria remains unchanged
- 530. CM Determine what changes the cardiac output undergoes in mitral stenosis?
- a. in mild and moderate mitral stenosis cardiac output is normal in patients with sinus rhythm at rest
- b. in mild and moderate mitral stenosis cardiac output is increased in patients with resting sinus rhythm
- c. in mild and moderate mitral stenosis the cardiac output is low in patients with sinus rhythm at rest
- d. loss of atrial contraction by installation of atrial fibrillation reduces cardiac output by up to 20%
- e. decreased cardiac output is clinically manifested by cyanosis
- 531. CM Mention the most common conditions of differential diagnosis in mitral stenosis:
- a. left atrial myxoma.
- b. atrial septal defect
- c. tricuspid stenosis
- d. ischemic heart disease
- e. lung cancer
- 532. CM Mention the categories of patients who can benefit from the restoration of sinus rhythm in case of mitral stenosis with atrial fibrillation:
- a. when atrial fibrillation occurs in a patient with wide mitral stenosis and the LA is less than 50 mm
- b. when atrial fibrillation greatly aggravates clinical phenomena and patients cannot be operated on
- c. when fibrillation persists after correction of the lesion
- d. when atrial fibrillation occurs after the correction of the lesion
- e. when atrial fibrillation occurs in a patient with wide mitral stenosis and LA is greater than 50 mm
- 533. CM Specify other names for mitral valve prolapse:
- a) Barlow syndrome
- b. telesystolic murmur click syndrome
- c. ballon mitral valve syndrome
- d. parachute mitral valve
- e. Eissenmeiger syndrome
- 534. CM List the characteristics of mitral valve prolapse:
- a. occurs more frequently in women
- b. occurs more frequently in men

- c. the most affected age is 20-30 years
- d. the most affected age is 50-60 years
- e. symptoms of the autonomic nervous system predominate
- 535. CM Note the pathogenic changes in aortic stenosis:
- a. decrease in cardiac minute-volume
- b. decreasing the length of LV systole
- c. thickening and shortening chordae tendineae
- d. increasing the pressure in the LV cavity
- e. concentric hypertrophy of the LV
- 536. CM Mention the objective signs characteristic of patients with a ortic insufficiency:
- a. systolic vibration
- b. the sign "Alfred de Musset"
- c. pulsation of the pupils
- d. the "dance" of the carotids
- e. the Quincke sign
- 537. CM Select which complications are characteristic of patients with aortic insufficiency:
- a. infectious endocarditis
- b. atrial fibrillation
- c. ventricular extrasystoles
- d. paroxysmal ventricular tachycardia
- e. epistaxis
- 538. CM Choose the pressure gradient in aortic stenosis depends on:
- a. the blood flow through the valve
- b. valve surface
- c. the contraction force of VS
- d. peripheral resistance
- e. the contraction force of the LA
- 539. CM Choose the pressure gradient in aortic stenosis depends on:
- a. the blood flow through the valve
- b. valve surface

- c. the contraction force of VS
- d. peripheral resistance
- e. the contraction force of the LA
- 540. CM Specify echocardiographic and Doppler criteria to assess the severity of severe aortic stenosis:
- a. valve area < 0.75 cm²
- b. instantaneous speed> 4.5 m/s
- c. peak gradient> 80 mmHg
- d) average gradient> 45 mmHg
- e. valve area> 0.75 cm2
- 541. CM Choose the complications characteristic of patients with tricuspid regurgitation:
- a. infectious endocarditis
- b. atrial fibrillation
- c. liver cirrhosis
- d. thrombosis
- e. epistaxis
- 542. Choose the specific features of severe tricuspid stenosis:
- a. the area of the tricuspid orifice is 1.2 cm²
- b. the area of the tricuspid orifice is 2 cm2
- c. the pressure gradient is 10 mmHg
- d. the pressure gradient is 5 mmHg
- e. the pressure gradient is 2 mmHg
- 543. CM Choose pathologies that can cause tricuspid stenosis:
- a. rheumatic fever
- b. infectious endocarditis
- c. carcinoid syndrome
- d. aortic coarctation
- e) endomyocardiofibrosis
- 544. CM Choose which of the following statements is correct for the LDL cholesterol fraction:
- a. the main form of transport of cholesterol in plasma, 60-70% of total plasma cholesterol

- b. constitutes 20-30% of the total cholesterol
- c. contains only one type of apoprotein (apo B-100)
- d. is atherogenic and proportionally correlated with the risk of cardiovascular events, independent of total cholesterol levels
- e. LDL particles function as a carrier of cholesterol from the liver to the arterial wall, cross the endothelial barrier and are absorbed by the macrophages of the intima ("foam cells")
- 545. CM Name how major risk factors have not been defined by the WHO:
- a. high prevalence in the population
- b. low prevalence in the population
- c. significant independent impact on the risk of ischemic coronary heart disease or stroke
- d. their treatment or control leads to a decrease in risk
- e, their treatment or control leads to an acceleration of the risk
- 546. CM Indicate which of the following statements are incorrect for dyslipidemia:
- a. is one of the factors with high prevalence and susceptibility to change
- b. includes a series of disorders of lipid metabolism with potential for induction and maintenance of atherosclerotic phenomenon
- c. refers to cardiovascular mortality and total cardiovascular events
- d. a better short- or long-term prognosis in overweight or obese patients
- e. is one of the factors with low prevalence and susceptibility to change

Correct answer: c, d, e

- 547. CM Name the causes of the abnormal automatism:
- a. extension of myocardial fibers
- b. changes in electrolyte balance
- c. the action of catecholamine's
- d. acute myocardial infarction
- e. 90 mV membrane potential
- 548. CM Mention what the Morgani-Adams-Stockes syndrome manifests in the "classic" version:
- a. tachyarrhythmia
- b. sudden onset
- c. syncopal condition with pronounced pallor
- d. reactive hyperemia after exiting the crisis

- e. transient character
- 549. CM Mention the incorrect statements regarding the I st degree AV block
- a. maintaining the conduction of all atrial impulses to the ventricles
- b. PQ or PR range greater than 0.2 mm / s
- c. is registered in the elderly
- d. PQ or PR interval below 0.12 sec.
- e. gradual elongation of the PQ interval
- 550. CM Mention the incorrect statements regarding the 2nd degree atrioventricular block, type I (Mobitz I):
- a. the absence of the Samoilov-Wenckebach periods
- b. the presence of the Samoilov-Wenckebach periods
- c. omission of 2, 3, 4 ventricular contractions while maintaining atrial contraction
- d) irregular RR intervals
- e. regular RR intervals